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Abstract 
Fumonisin B1 (FB1) is a mycotoxin produced by the fungus Fusarium verticillioides, which 
commonly infects corn and other agricultural products. Fusarium species can also be found in 
moisture-damaged buildings, and therefore there may also be human exposure to Fusarium 
mycotoxins, including FB1. 
FB1 is known to affect the metabolism of sphingolipids by inhibiting the enzyme ceramide 
synthase. It is neuro-, hepato- and nephrotoxic, and it is classified as possibly carcinogenic to 
humans. This study aimed to clarify the mechanisms behind FB1-induced neuro- and 
immunotoxicity. Four neural and glial cell lines of human, rat and mouse origin were exposed 
to graded doses of FB1. The effects on the production of reactive oxygen species, lipid 
peroxidation, intracellular glutathione levels, cell viability and apoptosis were investigated at 
different time points (0.5-144 h). Furthermore, the effects of FB1, alone or together with 
lipopolysaccharide (LPS), on the mRNA and protein expression levels of different cytokines 
and chemokines were studied in human dendritic cells (DC), differentiated from peripheral 
blood mononuclear cells. 
FB1 induced oxidative stress and cell death in all cell lines studied. However, the 
sensitivities of the cell lines varied depending on which parameter was being studied. 
Generally, the effects were only seen after prolonged exposure at 10 and 100 µM of FB1. 
Signs of apoptosis, reflected as increased caspase-3-like protease activity and internucleosomal 
DNA fragmentation, were also seen in all four cell lines. The results provide evidence that 
FB1 is a potential neurotoxin in vitro, but that the magnitude of the toxic effects is cell line 
dependent. The sensitivities of the cell lines used in this study towards FB1 may be classified 
as human U-118MG glioblastoma > mouse GT1-7 hypothalamic > rat C6 glioblastoma > 
human SH-SY5Y neuroblastoma cells. When comparing cell lines of human origin, it can be 
concluded that glial cells seem to be more sensitive towards FB1 toxicity than those of neural 
origin. 
After exposure to 100 µM FB1 for 6 or 24 h, significantly increased mRNA levels of the 
cytokine interferon-γ (IFNγ) were detected in human DC. This observation was further 
confirmed by FB1-induced mRNA levels of the chemokine CXCL9, which is known to be 
regulated by IFNγ. During co-exposure of DC to both LPS and FB1, significant inhibitions of 
the LPS-induced levels of the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-1β, and 
their regulatory chemokines CCL3 and CCL5 were observed. The results show that FB1 has 
  
 
 
the capacity to modulate the immune responses in DC. Therefore, it is rather likely that it also 
affects other types of cells participating in the immune defence system. 
When evaluating the toxicity potential of FB1, it is important to consider the effects on 
different cell types and cell-cell interactions. The results of this study represent new 
information, especially about the mechanisms behind FB1-induced oxidative stress, apoptosis 
and immunotoxicity, as well as the varying sensitivities of different cell types towards FB1. 
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Abbreviations 
Ac-DEVD-AMC acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin 
Cyt c  cytochrome c 
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DMEM  Dulbecco's Modified Eagle Medium 
DMSO  dimethyl sulphoxide 
DNA  deoxyribonucleic acid 
EDTA  ethylenediaminetetraacetic acid 
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Th  T helper 
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1 Introduction 
Mould growth is a common problem faced by farmers all over the world. In addition, much 
attention has been paid to the growth of microbes and moulds in moisture-damaged buildings 
(Hunter et al., 1988; Koskinen et al., 1999; McGrath et al., 1999; Peltola et al., 2001; Eduard, 
2006). The possible health effects associated with mould growth can be divided into three 
groups, i.e. allergic, infectious and toxic effects (Robbins et al., 2000).  
Filamentous fungi and moulds are able to produce an enormous number of secondary 
metabolites, including antibiotics. The term mycotoxin refers to those secondary metabolites 
which, at a low concentration, are toxic to humans and animals (reviewed by Hussein and 
Brasel, 2001; Bennett and Klich, 2003; Kuhn and Ghannoum, 2003). Low-molecular weight 
fungi metabolites that are toxic only at high concentrations are not considered to be 
mycotoxins. 
At present, about 300 to 400 mycotoxins have been identified (Bennett and Klich, 2003). 
The group of mycotoxins is extremely heterogenic with respect to both toxicity and chemical 
structure. The production of mycotoxins is highly dependent on the growth conditions, such 
as humidity, temperature and nutrient availability. Not all moulds produce mycotoxins, but 
one mould species may produce several different mycotoxins, or the identical mycotoxin may 
be produced by a number of different mould species (Robbins et al., 2000; Bennett and Klich, 
2003). The mycotoxins themselves are not essential for fungal growth but rather may be 
agents of chemical warfare to prevent microbial competitors competing for nutritive 
resources. Mycotoxins can occur in the mycelia, in the spores of the fungi or in the matrix in 
which the mould is growing (Wicklow and Shotwell, 1983; Hendry and Cole, 1993). 
The most frequent toxigenic fungi are Aspergillus, Penicillium and Fusarium (Creppy, 2002; 
Jarvis and Miller, 2005). These fungi produce the most important mycotoxins; aflatoxins 
(produced mainly by Aspergillus flavus and Aspergillus parasiticus), ochratoxin A (produced by 
Penicillium verrucosum, and by Aspergillus ochraeus, as well as by many other different species of 
Aspergillus), fumonisins (produced by Fusarium verticillioides and some other Fusarium species), 
deoxynivalenol (produced by Fusarium graminearum and Fusarium culmorum) and zearalenone 
(mainly produced by Fusarium graminearum and Fusarium culmorum but also by some other 
Fusarium species) (Creppy, 2002; Bennett and Klich, 2003). 
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Most of the studies on mycotoxins have been concerned with agricultural issues. 
However, lately some studies have also focused on the presence of mycotoxins in buildings 
and indoor air (Tuomi et al., 2000; Kuhn and Ghannoum, 2003; Nielsen, 2003; Institute of 
Medicine, 2004; Jarvis and Miller, 2005). It is believed that many of the non-specific 
symptoms (irritation of eyes, skin and respiratory tract; cough; headache; and fatigue) suffered 
by the residents of damp buildings may possibly be related to mycotoxins, and therefore 
analyses have been carried out to detect mycotoxins in building materials, household dust and 
indoor air (Cooley et al., 2004; Kilburn, 2004). 
In the present study, the focus was on studying mechanisms behind the toxic effects of 
one of the main Fusarium mycotoxins, namely fumonisin B1 (FB1). The biological effects of 
FB1 have been intensively studied during the last 15-20 years, and it has been demonstrated to 
be a compound which is both toxic and carcinogenic. Moreover, FB1 can cause fatal animal 
diseases (WHO, 2000, 2001). In this study, special attention was placed on investigating 
whether FB1 can cause oxidative stress and evoke apoptosis in cells of neural or glial origin, as 
well as clarifying the mechanisms causing these effects in these cell lines. This study also 
aimed to clarify whether exposure to FB1 can affect cytokine- and chemokine levels of human 
dendritic cells and in that way modulate the immune responses of these cells. 
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2 Review of the literature 
2.1 Group of fumonisin mycotoxins 
Fusarium verticillioides (=F. moniliforme) (Fig. 1) is one of the most prevalent fungi associated 
with contamination of corn throughout the world. In 1970, this strain was isolated from a 
batch of mouldy corn, believed to be the causative agent of a field outbreak of 
leukoencephalomalacia in horses in South Africa (reviewed by Marasas, 2001). Subsequently, 
the fungus was extensively studied, and finally in 1988, the mycotoxins named fumonisins 
were first isolated from cultures of F. verticillioides strain MRC 826 (Gelderblom et al., 1988). 
In the same year, the chemical structures of the fumonisins were also clarified (Bezuidenhout 
et al., 1988; Gelderblom et al., 1988). In addition to F. verticillioides, which is the major 
fumonisin-producing strain, fumonisins may also be produced by F. proliferatum, F. 
anthophilum, F. dlamini, F. napiforme and Alternaria alternata f. sp. lycopersici (Moss, 1998).  
 
 
 
 
 
 
 
Figure 1. Classification of Fusarium verticillioides. (Booth, 1971; Hawkswort et al., 1995). 
 
At least 15 different fumonisins have so far been reported, and they have been grouped 
into four main categories (A, B, C and P) (Dutton, 1996; WHO, 2000). The most abundant of 
the fumonisins is fumonisin B1 (FB1). However, the co-occurrence of small amounts of other 
mycotoxins, mainly FB2 and FB3, in FB1-containing samples is common. Since it is the most 
prevalent fumonisin compound, most of the studies published to date, as well as the present 
study, have focused on FB1. As the molecular structures of FB2 and FB3 are almost identical 
to that of FB1, it has been claimed that the magnitude of their toxicity may be at the same 
level as that of FB1 (Gelderblom et al., 1993; Norred et al., 1997; Voss et al., 1998; Howard et 
al., 2002). The importance of their toxicity is however marginal, as the levels of these 
compounds are usually very low. 
GROUP: Mitosporic fungi
(= Deuteromycetes = Fungi Imperfecti)
CLASS: Hyphomycetes – filamentous microfungi
SPECIES: Fusarium
STRAIN: Fusarium verticillioides (Sacc.) Nirenberg
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The molecules belonging to the group of naturally occurring fumonisin B compounds (FB1, 
FB2, FB3) consist of a long hydroxylated hydrocarbon chain, to which tricarballylic acid, 
methyl and amino groups are added (Fig. 2).  
 
CH3
CH3
OHR2
R1CH3
O
OOH
O
OH
NH2
O
O O
OH
O OH
CH3
O
 
  R1 R2 
Fumonisin B1 OH OH 
Fumonisin B2 H OH 
Fumonisin B3 OH H 
 
Figure 2. Molecular structures of some fumonisins. 
 
FB1 (C34H59NO15, relative molecular mass 721) is the diester of propane-1,2,3-tricarboxylic 
acid and 2-amino-12,16-dimethyl-3,5,10,14,15-pentahydroxyeicosane. The absolute 
stereochemical description of the molecule has been confirmed, and it shows that only one 
configuration exists for the tricarballylic acid units at both the C-14 and C-15 positions in the 
backbone. FB2 and FB3 also show the same configuration (ApSimon, 2001). It has been 
demonstrated that the primary amino group is necessary for the biological activity of 
fumonisin-like compounds, as acetylation of FB1 to FA1 blocks the cytotoxicity and the ability 
to inhibit ceramide synthase (see section 2.1.2.2). Moreover, hydrolyzed FB1 is only 30-40% 
as potent as normal FB1; highlighting the importance of the tricarballylic side chains 
(Gelderblom et al., 1993; Norred et al., 1997).  
Pure FB1 is a white hygroscopic powder, which is soluble in water, acetonitrile-water and 
methanol. It is unstable in methanol, and is stable at food processing temperatures and not 
broken down by exposure to light (WHO, 2000). Analyses of FB1 are usually performed by 
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high performance liquid chromatography (HPLC) of a fluorescent FB1-derivative. Other 
analytical methods used include thin-layer chromatography, mass spectroscopy, post-
hydrolysis gas chromatographic and immunochemical methods (WHO 2000, 2001). Studies 
on the biosynthesis of FB1 indicate that the synthesis route is somewhat similar to that of the 
sphingolipids. So far, no enzymes involved in the FB1-biosynthetic pathway have been 
isolated (Sweeney and Dobson, 1999; ApSimon, 2001). 
2.1.1 Occurrence of FB1 
FB1 has been detected in corn in all parts of the world (WHO, 1993; Dutton, 1996). The 
concentrations recorded vary enormously, but levels up to 300 mg/kg have been observed in 
corn feed in Hungary and in USA (Dutton, 1996; WHO, 2002). It has been estimated that the 
mean daily intake of FB1 may range between 12 and 140 µg per person, depending on 
geographical factors. However, there are individuals who may consume levels as high as 2500 
µg/day (WHO, 2001).  
In addition to corn, FB1 has also been detected in rice, sorghum, wheat bran, soybean 
meal and poultry feed (Bhat et al., 1997; Abbas et al., 1998; da Silva et al., 2000; Beg et al., 
2006). The natural occurrence of FB1 in Italian marketed foodstuffs has been analyzed, and 
positive samples were found among rice, flours, bread, breakfast cereals and biscuits (Cirillo 
et al., 2003a, b). The presumable occurrence of FB1 in wheat has been debated, but not 
confirmed, and the study of Shephard et al. (2005) emphasized the importance of validating 
the methods used for analyses of FB1.  
Fusarium moulds have also commonly been found in moisture-damaged buildings. When 
fungi were isolated from samples of buildings, 10.6% of the houses studied were 
contaminated with different Fusarium species. Fusarium verticillioides was found both in air 
samples and in samples taken from the walls (Hunter et al., 1988; Grant et al., 1989). In the 
study of Tuomi et al. (2000), it was reported that 15% of bulk samples of mouldy interiors 
taken from moisture-damaged buildings contained Fusarium species. Therefore, people living 
or working in buildings with mould problems may possibly be exposed to Fusarium 
mycotoxins, including FB1. 
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2.1.1.1 Tolerable daily intake 
The World Health Organization's International Programme on Chemical Safety (IPCS) and 
also the Scientific Committee on Food (SCF) of the European Commission have evaluated 
the risks related to FB1 and they have concluded that the tolerable daily intake (TDI) for FB1, 
FB2, and FB3, alone or in combination, is 2 µg/kg bodyweight per day (SCF, 2000, 2003; 
WHO, 2001). 
An official tolerance value (1 mg/kg FB1 + FB2) for dry corn products has been issued in 
Switzerland. In the USA, the Food and Drug Administration have provided recommended 
maximum levels of fumonisins in human foods and animal feeds. (FDA, 2001; WHO, 2002). 
2.1.2 Biochemical mechanisms of action of FB1 
2.1.2.1 Sphingolipids 
Sphingolipids are a class of lipids which can be found in all eukaryotic cells, where they serve 
as important structural molecules and act as regulators of a number of cell functions. 
Currently, over 300 sphingolipids have been identified, and they all contain a long-chain 
(sphingoid) base backbone. In mammalian cells, the most common sphingoid base is D-
erythro-sphingosine. Other frequently occurring sphingoid bases are sphinganine and 4-
hydroxysphinganine (Fig. 3) (Merrill et al., 1997). 
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CH3 OH
NH2
OH
 
Sphinganine 
CH3 OH
NH2
OH
 
Sphingosine 
CH3
NH
OH
CH3
O
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Dihydroceramide 
CH3
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OH
CH3
O
OH
 
Ceramide 
 
Figure 3. Molecular structures of sphinganine, sphingosine, dihydroceramide and ceramide. 
 
The sphingolipids are synthesized via a de novo pathway, as indicated in Fig. 4. The main 
step of the pathway includes the formation of sphinganine, which is then further acylated to 
dihydroceramide and ceramide (for structures, see Fig. 3), by the enzyme sphinganine N-
acyltransferase (ceramide synthase). The sphingolipid turnover involves the hydrolysis of 
complex sphingolipids to ceramide and further to sphingosine (Fig. 4). The initial steps of the 
biosynthesis route, from the condensation of serine and palmitoyl-coenzyme A (CoA) to the 
formation of ceramide, take place in the endoplasmic reticulum. Further processing of 
ceramide occurs in the endoplasmic reticulum and Golgi apparatus, whereas the degradation 
of complex sphingolipids takes place in lysosomes, endosomes and in the plasma membrane. 
Finally the degradation of free sphingoid bases occurs in the cytosol (see reviews Merrill et al., 
1996, 1997, 2001; WHO, 2000). 
  
 
 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The pathway of de novo sphingolipid biosynthesis and turnover in mammalian cells. 
Modified from Merrill et al. (1997); Riley et al. (2001); Soriano et al. (2005). 
 
The biochemical mechanisms and cellular effects of sphingoid bases and complex 
sphingolipids have been studied extensively. In general terms, they regulate cell growth, 
differentiation and apoptosis. The main effects of sphingolipids are summarized in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serine+Palmitoyl-CoA
Sphinganine
Dihydroceramide
Ceramide
Lipid products + 
phosphatidyl-
ethanolamine
Sphinganine 1-P
Sphingosine
Ceramide
Sphingosine 1-P
Glycosphingolipids
Sphingomyelin
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Table 1. Biological activities of sphingolipids 
Biochemical targets Cellular effects
Sphinganine and 
sphingosine
Inhibition of protein kinase C and 
phosphatidic acid phosphatase. 
Stimulation of phospholipase D. 
Calcium mobilization.
Regulation of cell growth, 
differentiation and apoptosis. 
Changes in cell morphology and 
altered cell permeability.
Sphinganine 1-
phosphate and 
sphingosine 1-
phosphate
Calcium mobilization. Altered 
intracellular cyclic AMP. 
Transcription of AP-1. Stimulation 
of phospholipase D.
Increased intracellular Ca2+ levels. 
Mediator of action of platelet-
derived growth factor.
Ceramide
Activation of protein kinases, 
phosphatases, MAP kinases, 
transcription factors. Inhibition of 
phospholipase D. 
Regulation of growth, differentiation, 
apoptosis, protein secretion. 
Mediator of action of TNFα, FAS 
ligand, IL-1, IFNγ.
Sphingomyelin, 
glycosphingolipids
Structural parts of membranes, 
extracellular matrix interactions.
Regulation of growth, trafficking of 
GPI anchored proteins. Modulation 
of cell-cell communication and cell 
adhesion.
Modified from Merrill et al. (1996, 1997); Riley et al. (2001).
GPI, glycosylphosphatidylinositol; AMP, adenosine 3',5'-monophosphate; 
AP-1, activator protein-1; MAP kinase, mitogen-activated protein kinase; 
TNFα, tumour necrosis factor-α; IL-1, interleukin-1; IFNγ, interferon γ.  
2.1.2.2 Inhibition of sphingolipid biosynthesis by FB1 
Fumonisins bear a clear structural similarity to the long-chain base backbones of 
sphingolipids (Figs. 1 and 2). Due to this similarity, Wang et al. (1991) hypothesized that 
disruption of sphingolipid metabolism might be a target for the fumonisins. These workers 
first showed that FB1 can inhibit de novo sphingolipid biosynthesis in primary rat liver 
hepatocytes, and that inhibition of the enzyme ceramide synthase plays a key role in this event 
(Wang et al., 1991). This investigation has been confirmed in many studies, demonstrating 
that FB1 can elevate urinary sphinganine and sphingosine levels in rats and serum levels in 
ponies consuming FB1-contaminated feed, sphinganine levels in kidney, liver and small 
intestine of mice administered FB1 subcutaneously, and cellular sphinganine and sphingosine 
levels in renal epithelial cells in vitro (Wang et al. 1992, 1999; Yoo et al., 1992; Riley et al., 
1994; Enongene et al., 2000). 
The inhibition of ceramide synthase by FB1, mainly results in elevated levels of 
sphinganine (Fig. 5), a sphingoid base which is normally present in cells at very low 
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concentrations (0.5-3 nmol/g wet weight). Moreover, ceramide synthase is also responsible 
for the reacylation of sphingosine derived from the turnover of more complex sphingolipids. 
Therefore, elevated levels of sphingosine, and possibly also sphingosine 1-phosphate, may be 
observed after exposure to FB1 (Fig. 5). These effects usually occur at a late stage, when there 
is extensive cell death and grossly disrupted sphingolipid turnover (reviewed by Merrill et al., 
1997, 2001; WHO, 2000; Riley et al., 2001; Soriano et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The sites of action of FB1-induced inhibition of the enzyme ceramide synthase. 
Modified from Merrill et al. (1997); Riley et al. (2001); Soriano et al. (2005). 
2.2 Toxic effects of FB1 
2.2.1 Effects in humans 
To date, there have been no reports about the kinetics and metabolism of FB1 in humans 
(WHO, 2000). The elimination of FB1 in mice is rapid, but as the rate of elimination is a 
function of body weight, it might possibly be much longer in humans (Delongchamp and 
Young, 2001). 
Serine+Palmitoyl-CoA
Sphinganine
Dihydroceramide
Ceramide
Phosphatidylethanolamine
Sphinganine 1-P
Sphingosine
Ceramide
FB1Ceramide synthase
Ceramide synthase
Sphingosine 1-P
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2.2.1.1 Human oesophageal cancer 
Epidemiologic studies in a number of countries in various regions of the world have revealed 
that the incidence of human oesophageal cancer and the occurrence of Fusarium verticillioides 
appear to correlate. Thus, the incidence of oesophageal cancer has been associated with a low 
socioeconomic status and less varied diets, consisting mainly of corn or wheat (WHO, 2000).  
Comparative studies performed in some parts of South Africa and China show that 
significantly higher levels of F. verticillioides, as well as concentrations of both FB1 and FB2, 
occur in the corn growing in areas with high incidence of oesophageal cancer, compared to 
the corn in low-risk areas (Sydenham et al., 1990; Chu and Li, 1994; Yoshizawa et al., 1994). 
Moreover, individuals with a high corn intake seem to be at a higher risk of developing 
oesophageal cancer than those with a low corn intake. Similar trends were also observed in 
studies with populations living in areas with a high incidence of oesophageal cancer in Iran, 
Italy, Kenya, Zimbabwe, USA and Brazil (reviewed by WHO, 2001). However, a prospective 
study on the relationship between sphingolipid levels and cancer incidence did not show any 
significant association between serum sphingolipids and the risk of oesophageal cancer, 
although sphingolipid levels are believed to function as biomarkers for FB1 exposure (Abnet 
et al., 2001). 
2.2.1.2 Neural tube defects 
In 1990-1991, an outbreak of neural tube defects (NTD; embryonic defects of the brain and 
spinal cord resulting from failure of the neural tube to close) occurred along the Texas-
Mexico border. Epidemiologists hypothesized that the outbreak might have been due to the 
high levels of FB1 observed in corn during the previous years (Hendricks, 1999; Missmer et 
al., 2006). Certain regions in China and South Africa, with high corn consumption, also have 
a high prevalence of NTD (Cornell et al., 1983; Ncayiyana, 1986; Moore et al., 1997). 
Missmer et al. (2006) reported that exposure to FB1, as estimated from postpartum 
sphinganine/sphingosine ratios and from maternal recall of corn tortilla intake before the 
pregnancy and during the first trimester, appeared to increase the risk of NTD. Moderate 
compared with low consumption of tortillas during the first trimester was statistically 
associated with an increased risk of having an NTD-affected pregnancy. 
In a study with Caco-2 cells, it was shown that the uptake of folic acid was dramatically 
inhibited after exposure to FB1 (Stevens and Tang, 1997). Exposure of mouse embryos to 
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FB1 inhibited sphingolipid synthesis and growth and caused NTD. Co-treatment with folic 
acid reduced NTD in mouse embryos by 65% in long-term experiments and by almost 50% 
in short-term experiments (Sadler et al., 2002). Furthermore, epidemiological studies as well 
as clinical trials have indicated that folate deficiency may be one major risk factor for NTD 
(Werler et al., 1999; Green, 2002; Blom et al., 2006). Therefore, it has been proposed that the 
disruption of sphingolipid metabolism caused by FB1 may affect folate uptake and result in an 
increased risk of NTD (Marasas et al., 2004). 
2.2.1.3 Acute mycotoxicosis 
Human consumption of rain-damaged mouldy sorghum and corn in 27 villages on the 
Deccan plateau in India in 1995 resulted in a food-borne disease outbreak characterized by 
abdominal pain and diarrhoea. In an epidemiological survey, the mycotoxicosis was 
connected to consumption of unleavened bread. The corn and sorghum samples from 
affected households were observed to be contaminated by Fusarium and Aspergillus fungi and 
contained high amounts of FB1, as compared with samples collected from unaffected 
households (Bhat et al., 1997). 
2.2.2 Effects in animals 
In vivo studies on the toxicity of FB1 indicate that liver and kidneys are the main target organs. 
Fumonisins are known to be poorly absorbed, rapidly eliminated via a two- or three-
compartment model, and not metabolized in animals (Martinez-Larranga, 1999; WHO, 2000, 
2001). In rats and pigs, FB1 is widely distributed, but small amounts have been found to 
accumulate only in liver and kidneys (Prelusky et al., 1996; Voss et al., 2001; WHO, 2001). In 
the gut of vervet monkeys, some of the FB1 has been shown to be partially hydrolyzed 
(WHO, 2000).  
2.2.2.1 Equine leukoencephalomalacia 
Leukoencephalomalacia (ELEM) is a neurotoxic disease of horses. It is characterized by 
liquefactive necrotic lesions predominantly in the white matter, but also to some extent in the 
grey matter, of the cerebrum. ELEM is a fatal disease, which apparently occurs only in horses. 
During the 20th century, outbreaks of this disease occurred sporadically in a number of 
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countries, for example in the USA as late as the 1980s. These outbreaks resulted in a number 
of studies, and finally in 1988, it was demonstrated that FB1 was the causative agent for this 
disease. Already in 1902, ELEM was reproduced experimentally by feeding mouldy corn, and 
the disease was called "mouldy maize poisoning" (Marasas et al., 1988; Marasas, 2001).  
After the fumonisins were isolated, it was shown that ELEM can be produced in horses 
by oral or intravenous administration of purified FB1 as well as by feeding naturally 
contaminated corn (Marasas et al., 1988; Kellerman et al., 1990; Wilson et al., 1992). The 
minimum oral dose sufficient to induce ELEM appears to be 15-22 mg/kg of diet (WHO, 
2000). In addition to the brain lesions, histopathological abnormalities are usually found in 
the liver (Ross et al., 1993). Elevated serum enzyme levels indicative of liver damage are 
normally preceded by an elevation in the sphinganine/sphingosine ratio (Wang et al., 1992; 
Wilson et al., 1992). Smith et al. (2002) observed an association between the neurological 
disease, serum and myocardial sphinganine and sphingosine concentrations, and a decline in 
cardiovascular function in horses. They suggested that the FB1-induced impairment of 
cardiovascular function may be one of the main factors contributing to the development of 
ELEM. 
2.2.2.2 Porcine pulmonary oedema 
Mycotoxin-induced pulmonary oedema in swine was first documented in 1981, after their 
exposure to corn contaminated by F. verticillioides. In the USA, thousands of pigs died from 
pulmonary oedema after ingestion of FB1-contaminated corn from the 1989 corn crop. Thus, 
the disease was named porcine pulmonary oedema (reviewed by Haschek et al., 2001).  
Porcine pulmonary oedema has been reproduced experimentally, and the FB1-induced 
toxicity in orally and intravenously dosed swine has been studied intensively. Alterations in 
sphingolipid biosynthesis have been observed, especially in lung, liver, kidney, and heart 
(Haschek et al., 1992, 2001). Pigs fed FB1-containing feed at concentrations of ≥ 92 ppm or ≥ 
16 mg/kg body weight/day developed lethal pulmonary oedema within 4-7 days (Harrison et 
al., 1990; Haschek et al. 1992, 2001). However, doses of 10 ppm may already have caused 
mild cases of pulmonary oedema (Zomborszky et al., 2000). FB1 has been shown to reduce 
the mechanical efficiency of the left ventricle and to block L-type calcium channels, this being 
hypothesized to be a result of increased sphingosine and/or sphinganine concentrations. 
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Therefore, it has been suggested that pulmonary oedema would primarily result from acute 
left-sided heart failure (Constable et al., 2000; Smith et al., 2000). 
2.2.2.3 FB1-induced toxicity in laboratory animals 
Feeding rats with FB1 for up to 90 days, or giving FB1 intraperitoneally for 4-11 days, has 
usually resulted in nephrotoxicity. Normally male rats seem to be more sensitive than females, 
but differences in sensitivity can also be detected between different rat strains (Riley et al., 
1994; Voss et al., 1995, 2001). The main finding in kidney has been apoptosis, which can 
initially be observed in the tubules of the outer medulla. In addition, tubular atrophy and 
regeneration, as well as decreased kidney weight have also been reported (Voss et al., 1995, 
2001). The cellular and histological effects were accompanied by changes in urine osmolality 
and urine enzyme levels (Suzuki et al., 1995; Bondy et al., 1998). The nephrotoxic effects in 
rats were closely correlated with disruption of sphingolipid metabolism and elevated urine 
levels of free sphingoid bases (Riley et al., 1994).  
In comparison to rats, mice do not appear to be very sensitive to the nephrotoxic effects 
induced by FB1 (Voss et al., 1995). At high doses, slight histological changes have been 
observed in mouse kidneys (Bondy et al., 1997). 
A number of research groups have reported histopathologic effects in rat livers after both 
short-term and long-term treatment with FB1. The initial finding has been apoptosis, 
characterized by small, rounded eosinophilic hepatocytes, but also necrotic hepatocytes were 
observed. Reduced liver weight, elevated serum alanine aminotransferase and cytoplasmic 
vacuolation of adrenal cortex are typical signs of hepatotoxicity. In general, female rats seem 
to be more sensitive than males (Gelderblom et al., 1988; Bondy et al., 1995, 1998; Voss et al., 
1995; Tolleson et al., 1996a; Lemmer et al., 1999).  
Also in mice, liver is one of the main target organs of FB1-induced toxicity. Female mice 
were more sensitive than males with the pathology being similar to that that observed in rats. 
The principal findings have included apoptosis and hepatocellular hyperplasia (Voss et al., 
1995, 2001; Howard et al., 2001a). 
The effects of FB1 on reproduction, studied in rats and in chicken eggs, indicate that FB1 
is not teratogenic, but it may possibly be embryotoxic at maternally toxic doses (reviewed by 
Voss et al., 2001). The possible genotoxicity of FB1 has been assessed in a number of studies, 
none of them indicating any mutagenic effects (reviewed by WHO, 2000, 2002). However, 
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FB1 may be able to damage DNA indirectly by increasing oxidative stress (Atroshi et al., 1999; 
Mobio et al., 2000a). 
2.2.2.4 Carcinogenic effects of FB1 in animals 
The potential carcinogenicity of FB1 has been studied in rats and mice, using either purified 
FB1 or using Fusarium verticillioides-contaminated culture material. 
In male BD IX rats, long term (up to two years) intake of 50 ppm FB1 resulted in the 
appearance of cholangiocarcinomas and hepatocellular carcinomas (Jaskiewicz et al., 1987; 
Gelderblom et al., 1991, 2001). In male F344 rats, no hepatocarcinogenic effects have been 
observed, but instead FB1 induced renal tubule tumours in this strain. Female F344 rats did 
not show any signs of carcinogenicity in a two-year feeding study, even at high concentrations 
such as of 100 ppm (Howard et al., 2001a). In female, but not in male B6C3F1 mice, FB1 has 
induced hepatocellular adenomas and carcinomas when the animals were fed 50 or 80 ppm 
FB1. 
As FB1 has been shown to be non-genotoxic, short term studies have been carried out to 
obtain information on the mechanisms responsible for cancer development. It is thought that 
the induction of renal and hepatic tumours could partly be due to the continuous 
compensatory regeneration of cells as a response to the apoptosis induced by FB1 (Howard et 
al., 2001b). Other important mechanisms which may be involved include oxidative damage 
and lipid peroxidation (Gelderblom et al., 2001). As with the toxic effects and the diseases 
caused by FB1, disruption of sphingolipid metabolism seems to be the causative factor 
accounting for FB1-induced carcinogenicity (Riley et al., 2001).  
The International Agency for Research on Cancer (IARC) has evaluated whether FB1 
should be classified as a carcinogenic compound. Based on animal studies and cases of 
human oesophageal cancer, IARC has evaluated FB1 as possibly carcinogenic to humans (Group 2B) 
(WHO, 1993, 2002). 
2.2.3 Comparison of FB1-induced toxic effects with key effects of 
other mycotoxins 
In addition to FB1, there are numbers of other mycotoxins, which are very important in terms 
of agriculture, food and occupational hygiene. Co-occurrence of many mycotoxins is 
common, and they may also show additive or synergistic effects (Tajima et al., 2002; Speijers 
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and Speijers, 2004; McKean et al., 2006). Aflatoxins have been the most extensively studied 
group of mycotoxins. Another well-known and important mycotoxin is ochratoxin A. The 
toxic effects of these compounds clearly differ from those of FB1.  
Aflatoxin B1 is the most potent natural carcinogen known, and it causes liver cancer both 
in humans and animals. In addition to its hepatocarcinogenicity, aflatoxin B1 can evoke 
hepatitis and childhood liver cirrhosis and is a potential immunosuppressant. (For reviews see 
WHO, 1993, 2002; Hussein and Brasel, 2001; Bennett and Klich, 2003).  
Ochratoxin A is recognized as a nephrotoxic compound. It causes renal damage in 
poultry, is acutely toxic and causes renal and hepatic tumours in rats and mice, and may 
promote urinary tract tumours in humans. Signs of genotoxicity have been observed both in 
vivo and in vitro. (Creppy et al., 1985; Hussein and Brasel, 2001; WHO, 2001; Bennett and 
Klich, 2003). 
The FB1-induced liver and kidney toxicity in rats and mice is quite similar to that induced 
by aflatoxins and ochratoxin A. However, the mechanisms behind the toxicities differ. So far, 
only the fumonisins have been shown to affect cells via the disruption of sphingolipids. 
Human oesophageal cancer, neural tube defects, equine leukoencephalomalacia and porcine 
pulmonary oedema appear to be specifically induced by FB1, as no other mycotoxins have 
shown any signs of causing these types of diseases (Hussein and Brasel, 2001; WHO 2001; 
Bennett and Klich, 2003; Kuhn and Ghannoum, 2003). 
2.3 Mechanisms of FB1-induced toxicity 
2.3.1 Involvement of oxidative stress in the FB1-toxicity 
2.3.1.1 Oxidative stress 
Organisms living in an aerobic environment are continuously exposed to reactive oxygen 
species (ROS). A variety of partially reduced metabolites of oxygen, called ROS, such as 
superoxide anion (O2-•), hydroxyl radical (•OH) and hydrogen peroxide (H2O2), are generated 
intracellularly as by-products of normal aerobic metabolism and second messengers of 
different signal transduction pathways (Finkel, 1998; Thannickal and Fanburg, 2000; 
Martindale and Holbrook, 2002). ROS are regarded as toxic by-products with an ability to 
cause damage to lipids, proteins and DNA (Lee and Wei, 2000). During normal conditions, 
the cells are able to protect themselves against these potentially damaging effects by removing 
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excessive ROS via different antioxidant pathways. Important antioxidant molecules include 
vitamins A, C and E, as well as glutathione (GSH; γ-glutamyl-L-cysteinglycine) (Dringen, 
2000). The enzymes participating in the elimination of ROS are superoxide dismutase, 
catalase and glutathione peroxidase (Thannickal and Fanburg, 2000; Martindale and 
Holbrook, 2002). 
The balance between ROS production and antioxidant defence determines the extent of a 
state called oxidative stress. Oxidative stress can be defined as an imbalance between ROS 
production and the antioxidant capacity. When the ability to remove ROS is not sufficiently 
effective, the free intracellular calcium levels may be elevated, GSH levels become depleted 
and cellular proteins, lipids and DNA may be affected. The severity of the damage depends 
on the cell type, the magnitude of the dose and the duration of the exposure. Typically, low 
doses of ROS can be mitogenic and promote cell proliferation, while intermediate doses 
result in growth arrest. High doses may cause dell death via either apoptotic or necrotic 
pathways (Halliwell, 1992; Finkel and Holbrook, 2000; Martindale and Holbrook, 2002). 
Exogenous sources responsible for elevated ROS production are for example ultraviolet light, 
ionizing radiation, chemotherapeutics, inflammatory cytokines, and environmental 
compounds, including toxins (Finkel and Holbrook, 2000). Survival depends on the ability of 
the cells and tissues to resist the stress and repair or remove damaged molecules or cells. 
Oxidative stress has been implicated in a number of human regeneration and disease 
processes including atherosclerosis, pulmonary fibrosis, cancer, different neurodegenerative 
diseases, and to be involved in normal ageing processes (Halliwell, 1992; Coyle and 
Puttfarcken, 1993; Finkel and Holbrook, 2000).  
GSH is the most important antioxidant cellular thiol compound, which in mammalian 
cells can be present at concentrations up to 12 mM. GSH has important detoxification 
functions and it also plays a role in the regulation of apoptosis (van den Dobbelsteen et al., 
1996; Ghibelli et al., 1998; Dringen, 2000). During detoxification of ROS, GSH reacts non-
enzymatically with radicals, and acts as an electron donor for the reduction of peroxides, this 
reaction being catalyzed by glutathione peroxidase. The oxidation of GSH results in the 
formation of glutathione disulfide, from which GSH can be regenerated in cells by a reaction 
catalyzed by glutathione reductase (reviewed by Cooper and Kristal, 1997; Dringen, 2000). 
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2.3.1.2 Oxidative damage induced by FB1 
The role of ROS production in FB1-mediated toxicity has not been studied to any significant 
extent. Galvano et al. (2002a, b) showed that exposure to 10-100 µM FB1 up to 72 h had no 
effect on the ROS production in human fibroblasts, or in primary cultures of rat astrocytes 
exposed to the same concentrations of FB1 for up to 6 days. Furthermore, a decreased 
production of H2O2 was observed both in peritoneal cells of rats and in adherent peritoneal 
cells in vitro (Theumer et al., 2002). 
Signs that FB1 may induce lipid peroxidation have been observed in studies performed in 
rat liver, monkey kidney cells, rat glioma cells, human intestinal cell line cells, and mouse 
embryonic fibroblasts (Abado-Becognee et al., 1998; Abel and Gelderblom, 1998; Sahu et al., 
1998; Mobio et al., 2000a, 2003; Kouadio et al., 2005). The doses inducing lipid peroxidation 
in these studies has varied from 0.14 µM for 24 h in monkey kidney cells (Abado-Becognee et 
al., 1998) to 20 µM for 24 h in human intestinal Caco-2 cells (Kouadio et al., 2005). In order 
to increase hepatic lipid peroxidation rats had to be fed with FB1 (doses of 250 or 500 mg/kg) 
for over 21 days (Abel and Gelderblom, 1998). Yin et al. (1998) observed that FB1 appeared 
to increase the rate of oxidation, to promote the production of free radicals, and to accelerate 
chain reactions associated with lipid peroxidation in membranes.  
Lowered GSH levels after exposure to FB1 have been observed in rat liver and spleen, and 
also in murine liver cells (Atroshi et al., 1999; Bondy et al., 1995, 1997). However, in some 
studies, GSH levels even increased in mouse kidneys and in rat livers after exposure to FB1 
(Bondy et al., 1995, 1997). 
2.3.2 Cytotoxic effects of FB1 
The effects of FB1 on cell viability have been studied in different types of cells. Cytotoxic 
effects have been observed for example in murine microglial cells and primary astrocytes 
(Osuchowski and Sharma, 2005), in rat glioblastoma cells (Mobio 2000a, 2003), in Chinese 
hamster ovary cells (Cetin and Bullerman, 2005), in human keratinocytes and oesophageal 
epithelial cells (Tolleson et al., 1996b), and in primary rat hepatocytes and rat liver in vivo 
(Abel and Gelderblom, 1998). In contrast to these results, FB1 did not induce cell death or 
any other signs of cytotoxicity in a cerebral cell aggregate culture (Monnet-Tschudi et al., 
1999), in rat astrocytes (Galvano et al., 2002b) or in human fibroblasts (Galvano et al., 2002a). 
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2.3.3 Apoptosis in the toxicity of FB1 
2.3.3.1 Apoptosis 
The main steps of the apoptotic pathways are summarized in Fig. 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The main pathways of events leading to apoptosis. For explanations, see text 
(section 2.3.3.1). Modified from Hengartner (2000); Bratton and Cohen (2001); Wang et al. 
(2005). 
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Apoptosis and necrosis are the main types of cell death. The term apoptosis was first 
introduced in 1972 (Kerr et al., 1972) to describe an active process characterized by cell 
shrinkage, nuclear and cytoplasmic condensation, and chromatin fragmentation. Usually the 
chromosomal DNA is initially degraded into large 50-300 kb subunits and subsequently into 
smaller units of about 180 base pairs (Wyllie et al., 1980). The apoptotic bodies formed can 
then be taken up and degraded by neighbouring cells. Normal tissue homeostatic cell deletion 
is, at least partly, controlled by apoptosis and allows the organism to control cell numbers and 
tissue size (Kerr et al., 1972; Wyllie et al., 1980). Apoptosis is also induced by different 
environmental factors, like chemicals, natural toxicants or radiation. 
Necrosis is a passive form of cell death, which is associated with cellular and organelle 
swelling, rupture of the plasma membrane, and leakage of cellular contents into the 
extracellular matrix, often resulting in inflammation (reviewed by Robertson and Orrenius, 
2002). 
Apoptosis may take place either via a death-receptor pathway or via a mitochondrial 
pathway (Fig. 6). The death-receptor pathway is activated by binding of a ligand to the CD95 or 
to the tumour necrosis factor (TNF) receptor, recruitment of FADD (Fas-associated death 
domain) or TNFADD (TNF receptor-associated death domain) and procaspase-8 molecules, 
resulting in caspase-8 activation. Caspase-8 can then activate caspase-3, resulting in the 
activation of the DNA ladder nuclease, called caspase-activated DNase, followed by nuclear 
condensation and DNA fragmentation. 
The mitochondrial pathway is activated both as a response to extracellular conditions as well 
as to internal insults such as DNA damage. These factors increase the levels of the tumour 
suppressor p53 and the pro-apoptotic protein Bax, activating release of cytochrome c from 
mitochondria. The release can be inhibited by anti-apoptotic members of the Bcl-2 family. 
The released cytochrome c (Cyt c) molecules associate with Apaf-1 and procaspase-9, to form 
a complex called an apoptosome. As in the death-receptor pathway, the final steps include 
activation of caspase-3 followed by morphological changes. Cross-talk between the two 
pathways is provided by the protein Bid, a pro-apoptotic Bcl-2 family member, which is 
activated by caspase-8, and which is further translocated to mitochondria where it promotes 
the release of cytochrome c. The effects of Bid on mitochodria may be inhibited by the anti-
apoptotic protein Bcl-XL. (For reviews, see Hengartner, 2000; Robertson and Orrenius, 2000, 
2002; Bratton and Cohen, 2001; Wang et al., 2005). 
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2.3.3.2 FB1-induced apoptosis 
Apoptosis induced by FB1 (shown mainly as caspase-3 activation or DNA fragmentation) has 
been observed in a number of cell types and tissues, including human keratinocytes, liver and 
kidney of rats (Tolleson et al., 1996a, b), human colonic cell line cells (Schmelz et al., 1998), 
human fibroblasts (Galvano et al., 2002a), human proximal tubule-derived cells (Seefelder et 
al., 2003), and rat glioblastoma cells (Mobio et al., 2000b, 2003). However, neoplastic monkey 
kidney cells or murine and human leukaemia cells do not undergo apoptosis when treated 
with FB1 (Bose et al., 1995; Wang et al., 1996; Ciacci-Zanella et al., 1998). It has also been 
shown that the induction of apoptosis by FB1 can be mediated by the accumulation of free 
sphingoid bases, but inhibition of ceramide synthase alone is, however, not responsible for 
the induction of apoptosis (Schmelz et al., 1998; Seefelder et al., 2003). 
Some studies have focused on the mechanisms whereby FB1 may induce apoptosis. 
Studies with human neonatal kidney cells, human lung fibroblasts, and green monkey kidney 
fibroblasts have indicated that FB1-induced apoptosis does not involve p53 or Bcl-2 family 
proteins (Ciacci-Zanella and Jones, 1999; Jones et al., 2001). However, in mouse liver, the 
expressions of Bcl-2 and Bax were increased after exposure to FB1 (Bhandari and Sharma, 
2002a). No apoptotic effects could either be observed in p53-null mouse embryonic 
fibroblasts (Mobio et al., 2003). Moreover, increased expression of caspase-8 and the 
production of pro-inflammatory cytokines like TNFα seem to be important mediators of FB1-
induced apoptosis in murine liver or primary hepatocytes (Bhandari and Sharma, 2002b; 
Sharma et al., 2005). 
2.3.4 Immunotoxic effects of FB1 
2.3.4.1 Cytokines 
Cytokines are secreted proteins which regulate the nature of immune responses by affecting 
growth, differentiation and activation of cells (Table 2). Cytokines are involved in almost all 
stages of immunity and inflammation and their production is induced by a variety of stimuli 
such as viral, bacterial or parasitic infection, cancer, inflammation, or the interaction between 
T cells and antigens. The biological actions of cytokines are produced when they act as 
ligands and bind to their high-affinity receptors. Cytokines can act 1) in an autocrine manner, 
affecting the cell that releases the cytokine, 2) in a paracrine manner, affecting nearby cells, or 
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3) in an endocrine manner, affecting distant cells after their distribution via the blood 
circulation. (Prescott et al., 2002; Borish and Rosenwasser, 2003). 
 
Table 2. Classification of cytokines according to their biological activities. 
Cytokine Biological function
Pro-inflammatory cytokines  
IL-1β, IL-1α, IL-6, TNFα, IL-12, IL-18, IFNγ Activation of B- and T-lymphocytes, leukocytes, 
epithelial and endothelial cells. Strengthening of 
inflammatory reactions.
Anti-inflammatory cytokines
IL-4, IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, 
TGFβ
Inhibition of the production of pro-inflammatory 
cytokines. Anti-proliferative. 
Interferons
IFNα, IFNβ, IFNγ Antiviral compounds. Immunomodulation and 
inhibition of cell growth.
Th1-cytokines
IL-2, IL-12, IL-15, IL-18, IL-21, IL-23, IFNα, 
IFNγ
Strengthening cell-mediated immunity. Th1-cell 
differentiation. Activation of natural killer cells 
and macrophages. Increasing IFNγ.
Th2-cytokines
IL-4, IL-5, IL-10, IL-13 Strengthening antibody-mediated responses. 
Differentiation and growth of B- and Th2-cells. 
Stimulation of eosinophils. Inhibition of Th1-
cells.
Chemokines
see section 2.3.4.2 Induction of chemotaxis of different cells.
Growth factors
Erythropoietin, M-CSF, G-CSF, GM-CSF Maturation of erythroid cells. Differentiation and 
proliferation of neutrophils and monocytes. 
Activation of mature monocytes and 
macrophages.
Modified from Mire-Sluis and Thorpe (1998); Prescott et al. (2002);    
Borish and Rosenwasser (2003); Borish and Steinke (2003); Steinke and Borish (2006).
 
IL: interleukin, IFN: interferon  
 
Grouping cytokines according to tissue sources or biological activities is complicated 
because many cytokines are produced by different types of cells and, in addition, many of the 
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cytokines can have different kinds of biological effects, for example having both pro- and 
anti-inflammatory properties (Borish and Steinke, 2003). Table 2 shows an example of 
cytokines grouped according to their biological activities.  
2.3.4.2 Chemokines 
Chemokines are a group of cytokines known to induce chemotaxis in a variety of cells. The 
human chemokine family consists of over 40 compounds, which all regulate activity through 
interactions with members of the G-protein-coupled receptor family. Moreover, 18 
chemokine receptors have been described, many of which can bind to more than one 
chemokine (Borish and Steinke, 2003; Rot and von Andrian, 2004). 
The chemokines can be divided into four subfamilies, based on the positioning of the N-
terminal cysteine residues. The largest two groups are the CXC-family (CXCL1-CXCL16), 
which primarily is targeting neutrophils, and the CC-family (CCL1-CCL28), which focuses on 
monocytes and T-cells. The two other subfamilies include the C-family (XCL1 and XCL2, 
targeting lymphocytes) and the newest, the CX3C-family (at present, containing only one 
compound, CX3CL1, which is membrane-bound) (Borish and Steinke, 2003; Zimmermann et 
al., 2003; Esche et al., 2005). 
Traditionally, chemokines have been considered as inflammatory compounds, produced 
at the site of infection or as a response to pro-inflammatory stimuli. Subsequently, a 
homeostatic or housekeeping function was also described, including involvement in adaptive 
immune responses such as lymphocyte trafficking (Moser and Loetscher, 2001; Moser et al., 
2004). 
2.3.4.3 Effects of FB1 on cytokine levels 
The current state of knowledge indicates that FB1 can have marked immunological effects. 
The effects of FB1 on the cytokine profile of different organs and different cell types have 
been described in a number of publications. An increased expression of TNFα and 
interleukin-1β (IL-1β) has been detected in mouse liver and kidney, and also in primary 
cultures of hepatic cells after exposure to FB1. In addition, FB1 can increase the expression of 
interferon-γ (IFNγ), IL-1α, IL-6, IL-10, IL-12 and IL-18 in mouse liver (Bhandari et al., 
2002a,b; Sharma et al., 2005). However, FB1 may decrease the lipopolysaccharide (LPS)-
induced brain and liver expression of IFNγ and IL-1β (Osuchowski et al., 2005). Elevated 
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TNFα expression, after activation of the cells with LPS in vitro, has also been observed in 
peritoneal macrophages of mice and in mouse macrophage cell line cells treated with FB1 
(Dugyala et al., 1998). On the contrary, FB1-exposure has resulted in significantly decreased 
mRNA levels of TNFα and IL-1β in swine alveolar macrophages (Liu et al., 2002). 
Furthermore, some studies in pigs into effects of FB1 on cytokines have also been 
reported. An increased expression of IL-8, IL-18 and IFNγ mRNA was observed in the 
bronchoalveolar lavage fluid of swine orally gavaged with FB1, (Halloy et al., 2005). Moreover, 
short duration FB1-exposure of piglets, as well as in vitro exposure of pig peripheral blood 
mononuclear cells (PBMC) resulted in decreased levels of IL-4 and increased levels of IFNγ 
(Taranu et al., 2005). 
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3 Aims of the study 
FB1 is known to be toxic to different types of cells and tissues, but the mechanisms whereby 
it exerts its toxicity have not fully been clarified. In this study, the focus has been on 
neurotoxicity and immunotoxicity induced by FB1 in different types of cells in vitro. The 
effects of FB1 on oxidative stress, cell viability and apoptosis have been studied in four neural 
and glial cell lines of human, mouse and rat origins. Immunotoxic effects have been studied 
by measuring the expression of cytokines and chemokines in human dendritic cells after 
exposure to FB1. 
 
The specific aims of this study were: 
 
1. To evaluate the role of ROS production, lipid peroxidation and intracellular glutathione 
levels in oxidative stress caused by FB1 in neural and glial cell lines (I, II). 
 
2. To evaluate the effect of FB1 on the viability of neural and glial cell lines (I, II). 
 
3. To clarify whether FB1 causes apoptosis, and which apoptosis-related pathways are 
involved in its toxicity, in neural and glial cell lines (II, III). 
 
4. To investigate mechanisms whereby FB1 may induce immunotoxic effects, by studying 
alterations in cytokine and chemokine expressions in dendritic cells (IV). 
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4 Materials and methods 
More detailed information on materials and methods are presented in the original 
publications I-IV. 
4.1 Cell culture 
4.1.1 Neural and glial cell lines (I, II, III) 
For the studies on neurotoxicity, different types of cell lines, originating from different source 
species, were chosen to obtain a wide perspective on the effects of FB1. The cell lines used 
were: human U-118MG glioblastoma cells (obtained from the American Type Culture 
Collection), human SH-SY5Y neuroblastoma cells, mouse GT1-7 hypothalamic cells and rat 
C6 glioblastoma cells (kind gifts from Dr. S. Påhlman, University of Uppsala, Sweden; Dr. P. 
Mellon, University of California, USA; and Dr. N. Plesnila, University of Munich, Germany, 
respectively). 
U-118MG, SH-SY5Y and C6 cells are well-known, established cell lines derived from 
neuronal or glial tumours, whereas GT1-7 is an immortalized mouse hypothalamic cell line. 
SH-SY5Y and GT1-7 cells have neuronal morphological characteristics and express markers 
and receptors for neuronal cells, (Ross et al., 1983; Mellon et al., 1990, Spergel et al., 1994; 
Nair et al., 1996), whereas U-118MG and C6 cells possess characteristics typical of glial cells 
(Benda et al., 1968; Pontén and Macintyre, 1968; Minghetti et al., 1996; Sibenaller et al., 2005). 
All cell lines were cultured in Dulbecco's Modified Eagle Medium (DMEM), 
supplemented with 10% inactivated foetal bovine serum, 50 U/ml penicillin and 50 µg/ml 
streptomycin (all from Gibco, Paisley, UK), at 37 ºC in 5% CO2 in an air-ventilated 
humidified incubator. The cells were cultured in 75 cm2 cell culture flasks and harvested in 
three different solutions; 0.25% trypsin (Gibco) in phosphate buffered saline (PBS) (U-
118MG cells), by 0.02% ethylenediaminetetraacetic acid (EDTA) (Sigma Co., St, Louis, MO, 
USA) in PBS (SH-SY5Y cells), or a solution containing 0.05% trypsin and 0.02% EDTA in 
PBS (GT1-7 and C6 cells). The cells were sub-cultured for a maximum of three months to 
assure the stability of the cell cultures. 
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4.1.2 Human dendritic cells (IV) 
Peripheral blood mononuclear cells (PBMC) were isolated from standard buffy coats of 
healthy blood donors (obtained from the Finnish Red Cross Blood Transfusion Service, 
Helsinki, Finland) by density gradient centrifugation with LymphoprepTM (Axis-Shield PoC 
AS; Oslo, Norway) followed by density gradient centrifugation with PercollTM (Amersham 
Biosciences; Uppsala, Sweden). A total of 3x106 PBMC cells were allowed to adhere onto 6-
well plates in 3 ml of serum-free RPMI 1640 medium, supplemented with 20 mM Hepes, 50 
U/ml penicillin and 50 µg/ml streptomycin (all from Gibco), for 1 h at 37 ºC. The medium 
and any non-adherent cells were then removed, and the adherent cells were cultured for 5 
days with 50 ng/ml GM-CSF and 1000 U/ml IL-4 (R&D Systems; Abingdon, UK) in 3 ml of 
RPMI 1640 medium, supplemented with 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml 
streptomycin and 10% inactivated foetal bovine serum at 37 ºC in 5% CO2 in an air-ventilated 
humidified incubator. Then the cells were exposed to FB1 or LPS, and after the exposures, 
the cells were collected and the cell culture medium was stored at -20 ºC for the ELISA 
(enzyme-linked immunosorbent assay) analyses. Finally, dendritic cells (DC) were purified by 
positive sorting using anti-CD1a-conjugated magnetic microbeads (Miltenyi; Bergisch 
Gladbach, Germany) and stored in Trizol (Invitrogen technologies, Paisley, UK) at -70 ºC for 
RNA isolation. To obtain an indication on the maturation status of DC, the mRNA 
expression of CD86 was studied by quantitative real-time PCR (see section 4.5.1). 
4.1.3 Exposure of cells 
For the treatments, cells were cultured on well plates and exposed to graded doses (0.01-100 
µM) of FB1 (Sigma; >98% purity) in dimethyl sulphoxide (DMSO) for 0.5-144 h. Control 
cells were incubated for the same time periods with DMSO at a concentration of 1%. A 
scheme on the different experiments is presented in Table 3. 
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Table 3. Summary of FB1 concentrations, exposure times and conditions used in this study. 
Measurement Wells / 
plate
Cells / ml 
medium / well
FB1 
concentrations
Time points Study
Reactive oxygen 
species (ROS)
48 1-2x105/0.5 ml 0.01, 0.1, 1, 10, 
100 µM
0.5, 1, 2, 3, 4, 5, 
12, 24, 48, 72, 
144 h
I, II
Glutathione (GSH) 48 1-2x105/0.5 ml 0.01, 0.1, 1, 10, 
100 µM
0.5, 1, 2, 3, 4, 5, 
12, 24, 48, 72, 
144 h
I, II
Lipid peroxidation 24 2-3x105/1 ml 0.01, 0.1, 1, 10, 
100 µM
0.5, 1, 2, 3, 4, 5, 
12, 24, 48, 72, 
144 h
I, II
Viability 48 1-2x105/0.5 ml 0.01, 0.1, 1, 10, 
100 µM
0.5, 1, 2, 3, 4, 5, 
12, 24, 48, 72, 
144 h
I, II
Caspase-3-like 
protease activity
6 1.5-3x106/3 ml 0.01, 0.1, 1, 10, 
100 µM
0.5, 1, 2, 3, 4, 5, 
12, 24, 48, 72, 
144 h
II, III
Internucleosomal 
DNA fragmentation
6 1.5-3x106/3 ml 0.1, 1, 10, 30, 100 
µM
24, 48, 72, 144 
h
II, III
p53 protein 9 cm petri 
dish
3-5x106/10 ml 100 µM 72 h III
Bcl-2 family proteins 6 4-8x105/1 ml 1, 10, 30, 
100 µM
24, 48, 72, 144 
h
III
Cytokines and 
chemokines
6 3x106/3 ml 100 µM FB1, 
10 ng/ml LPS, 
100 µM FB1+
10 ng/ml LPS
6, 24 h IV
 
4.2 Determination of oxidative stress 
4.2.1 Measurement of reactive oxygen species (ROS) (I,II) 
For measuring ROS production, the cells were loaded with 2',7'-dichlorodihydrofluorescein 
diacetate (McIntosh and Sapolsky, 1996; Loikkanen et al., 1998). After culturing of the cells, 
the medium was removed and replaced with Hank's balanced salt solution (HBSS), and the 
cells were then loaded with 2',7'-dichlorodihydrofluorescein diacetate (Molecular Probes Inc., 
Eugene, OR, USA). In long-term experiments (12 h or longer), FB1 incubations were carried 
out in DMEM at 37 ºC before the addition of 2',7'-dichlorodihydrofluorescein diacetate, and 
in short-term experiments (0.5-5 h) in HBSS at room temperature after inclusion of the 
  
 
 
37
probe. The formation of the fluorescent compound, 2',7'-dichlorofluorescein, was monitored 
at an excitation wavelength of 485 nm and an emission wavelength of 535 nm using a Wallac 
Victor II Multilabel Counter (Wallac, Finland). Background fluorescence was obtained from 
cell-free wells treated similarly as the samples. To normalize the fluorescence values to the 
total cell number, the 2',7'-dichlorofluorescein values were divided by the fluorescence values 
obtained after the addition of propidium iodide and digitonin (Fmax, see section 4.3). The 
normalized fluorescence values were used to calculate ROS production as a percent of 
control at each time point. 
4.2.2 Determination of lipid peroxidation (I,II) 
Lipid peroxidation was measured as the amount of malondialdehyde (MDA) produced in cells 
after incubations with FB1. The incubations were carried out on 24-well plates, after which 
the cells were collected and re-suspended in SET buffer (0.1 M NaCl, 29 mM EDTA, 50 mM 
Tris-HCl, pH 8.0).  
The method described by Baudrimont et al. (1997) was used for the formation and 
extraction of MDA-thiobarbituric acid (TBA) adducts from the cell samples. MDA standards 
(concentration ranges 3.9-125 nM) were prepared using a 250 nM 1,1,3,3-
tetramethoxypropane (=malonaldehyde bis(dimethyl acetal)) solution (Sigma) in SET buffer. 
The MDA-TBA adducts were extracted from samples and standards with n-butanol, before 
analysis by high performance liquid chromatography (HPLC) with fluorometric detection 
(RF-10AXL fluorescence detector, Shimadzu, Germany). To ensure the accuracy of the 
results, much attention was paid to modifying the HPCL-method used by Matias et al. (1999). 
The optimal excitation wavelength was observed to be 515 nm and the emission wavelength 
544 nm. Also the flow rates, pH and gradients used were adjusted to achieve stable retention 
times and maximal separation of MDA-TBA adducts. To obtain linear 6-point MDA 
calibration curves, areas of blank samples were subtracted from peak areas of standards. The 
concentrations of MDA in the samples were calculated using the standard curves, after 
subtracting blank areas from sample areas. 
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4.2.3 Measurement of glutathione (GSH) (I, II) 
For studying intracellular GSH levels, the cells were treated with monochlorobimane (mBCl) 
(Sarafian et al., 1994; Loikkanen et al., 1998). In long-term experiments (12 h or longer), the 
cells were incubated with FB1 in DMEM at 37 ºC, and in short term (0.5-5 h) experiments in 
HBSS at room temperature. After the incubations, the cells were loaded with 40 µM mBCl 
(Molecular Probes), and the formation of the fluorescent GSH-mBCl complex was 
monitored at an excitation wavelength of 355 nm and an emission wavelength of 460 nm 
(Wallac Victor II). Cell free wells served as blanks, and their fluorescence values were 
subtracted from those of the cell samples. Fluorescence values were normalized to total cell 
number of each well, based on the maximal PI fluorescence value (Fmax, see section 4.3). 
Using normalized fluorescence values, the levels of GSH were calculated as a percent of 
control at each time point. 
4.3 Determination of cell viability (I, II) 
After incubating the cells with FB1, 50 µM of propidium iodide (PI) (Molecular Probes) was 
added for the detection of cell viability (Sarafian et al., 1994; Loikkanen et al., 1998). PI is 
impermeable to intact membranes, but binds to the nucleic acids of dead cells, leading to 
major increase in its fluorescence. The fluorescence (F) was measured at an excitation 
wavelength of 530 nm and an emission wavelength of 590 nm using a Wallac Victor II 
Multilabel counter. Thereafter, 160 µM of digitonin (Molecular Probes) was added to 
permeabilize the cells and obtain 100% cell death. The maximal fluorescence value (Fmax) was 
then measured using the same wavelengths. Background fluorescence was obtained from cell 
free wells containing PI (blank1) or PI+digitonin (blank2). The equation used for calculating 
percentual viability was:  
Viability (%) =100 - [(F- blank1) / (Fmax- blank2)] x 100. 
4.4 Detection of apoptotic cell death 
4.4.1 Caspase-3-like protease activity (II, III) 
The caspase-3 substrate, acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-
AMC) (Calbiochem, La Jolla, CA, USA), was used for measuring caspase activity (Pulkkanen 
et al., 2000; Movsesyan et al., 2002). Activated caspase-3 (and also some other caspases) 
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recognizes the peptide sequence of Ac-DEVD-AMC, resulting in cleavage of the fluorescent 
AMC. 
After exposure, the cells were collected and re-suspended into a lysis buffer (10 mM Tris, 
1% Triton X-100 in PBS, pH 7.5) on ice. Then, 25 µg of protein (determined by the method 
of Lowry et al. (1951), using Bio-Rad reagents, Hercules, CA, USA) was incubated with 15 
µM Ac-DEVD-AMC in an assay buffer (20 mM Hepes, pH 7.5, 2 mM dithiotreitol, 10% 
glycerol). Thereafter, the substrate cleavage was measured in black 96-well plates at an 
excitation wavelength of 355 nm and an emission wavelength of 460 nm using a Wallac 
Victor II Multilabel counter. The fluorescence values of cell free wells containing Ac-DEVD-
AMC were subtracted from those of the samples. The caspase-3-like activity was expressed as 
the fluorescence values calculated, which were corrected with the cell viability values obtained 
as described in section 4.3. 
4.4.2 Internucleosomal DNA fragmentation (II, III) 
DNA fragmentation was studied by isolating DNA from cells according to Herrmann et al. 
(1994). After incubation with FB1, cells were mixed with a lysis buffer (0.25% Nonidet P-40, 1 
mM EDTA, 40 mM Tris, 0.1% acetic acid), centrifuged, and treated with RNAse A (Sigma) 
and proteinase K (Roche Diagnostics, Mannheim, Germany). Thereafter, the DNA fragments 
were separated by electrophoresis in 1.5% agarose gel. After ethidium bromide staining, the 
DNA was visualized under UV-light. 
4.4.3 Immunoblotting of p53 protein (III) 
After exposure, the cells were suspended into cytoplasmic lysis buffer (20 mM HEPES, pH 
7.6, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM dithiotreitol, 500 µM 
PMSF, 1 µg/ml aprotinin, 1 µg/ml antipain, 0.7 µg/ml pepstatin) on ice, centrifuged, and the 
cytoplasmic supernatants were collected. The cell pellets were then suspended into a nuclear 
lysis buffer (identical to the cytoplasmic lysis buffer, but containing 500 mM NaCl) on ice, 
and after centrifugation, the nuclear extracts were obtained.  
For the immunoblotting, 20 µg of protein was separated electrophoretically in a 12% 
polyacrylamide gel (SDS-PAGE, Mini Protean 3, Bio-Rad). The proteins were transferred 
onto polyvinylidene fluoride membrane by electroblotting on a Mini-Trans-Blot cell (Bio-
Rad). To block unspecific binding, the membrane was incubated in 5% non-fat milk in Tris-
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buffered saline (TBS; 50 mM Tris, 200 mM NaCl, pH 7.4) overnight at 4 ºC. For human cells 
(U-118MG and SH-SY5Y) mouse antihuman monoclonal DO-7 (dilution 1:2000; Novocastra 
Laboratories, Newcastle, UK) was used as primary antibody and Anti-mouse IgG (dilution 
1:2800; Amersham Pharmacia Biotech, Buckinghamshire, UK) was used as the secondary 
antibody. For murine cells (GT1-7 and C6) mouse monoclonal Pab 240 (dilution 1:200; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) and Anti-mouse IgG (1:2800) were used as 
primary and secondary antibodies, respectively. Protein bands were detected with 
chemiluminescent ECL+ Western blotting reagents (Amersham Pharmacia Biotech) 
according to the manufacturer's instructions. 
4.4.4 Immunoblotting of Bcl-2 family proteins (III) 
The cells were incubated with FB1, washed with PBS, collected and protein concentrations 
were determined (Lowry et al., 1951). From the cells exposed to FB1 for 144 h, the nuclear 
and cytoplasmic fractions were separated as described in section 4.4.3 
For the determination of Bax, Bcl-2, Bcl-X and Mcl-1 expression, 75 µg of proteins were 
separated electrophoretically in a 12% polyacrylamide gel (SDS-PAGE; Mini Protean II, Bio-
Rad). The separated proteins were transferred from the gels onto nitrocellulose membranes 
by electroblotting on a Mini-Trans-Blot cell (Bio-Rad). The membranes were incubated in 5% 
non-fat milk powder to block unspecific binding. For antibodies see Table 4.  
All primary antibodies were obtained from Pharmingen (San Diego, CA, USA). Anti-
rabbit IgG was from Jackson ImmunoResearch laboratories Inc. (West Grove, PA, USA) and 
anti-mouse IgG was from Amersham Pharmacia Biotech. As the loading control, β-actin 
expression was detected with a monoclonal anti-actin antibody (1:30000; Sigma) followed by 
anti-mouse IgG (1:3000) as secondary antibody. 
Protein bands were detected with chemiluminescent ECL Western blotting detection 
reagents according to the manufacturer's instructions. 
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Table 4. Antibodies and dilutions used for immunoblotting of Bcl-2 family proteins. 
Protein detected Primary antibody             
(dilution)
Secondary antibody 
(dilution)
GT1-7 and C6 cells  
Bax Polyclonal rabbit anti-
mouse/rat Bax (1:8000)
Anti-rabbit IgG                
(1:25000)
Mcl-1 Anti-mouse/rat Mcl-1 
(1:1000)
Anti-mouse IgG               
(1:4000)
Bcl-2 Polyclonal rabbit anti-
mouse Bcl-2 (1:5000)
Anti-rabbit IgG                
(1:15000)
Bcl-X Purified mouse 
monoclonal anti-Bcl-X 
(1:1000)
Anti-mouse IgG               
(1:4000)
 
U-118MG and SH-SY5Y cells
Bax Polyclonal rabbit anti-
human Bax (1:5000)
Anti-rabbit IgG                
(1:15000)
Mcl-1 Polyclonal rabbit anti-
human Mcl-1 (1:3000)
Anti-rabbit IgG                
(1:10000)
Bcl-2 Polyclonal rabbit anti-
human Bcl-2 (1:5000)
Anti-rabbit IgG                
(1:10000)
Bcl-X Purified mouse 
monoclonal anti-Bcl-X 
(1:1000)
Anti-mouse IgG               
(1:4000)
 
4.5 Determination of cytokine and chemokine 
expression 
4.5.1 Real-time mRNA analysis (IV) 
Total RNA of DC was isolated according to the manufacturer's instructions (Trizol; 
Invitrogen technologies, Paisley, UK). The RNA samples were then incubated with RNase 
free DNaseI (Roche) to remove contaminating genomic DNA. One microgram of total RNA 
was reverse transcribed using MultiScribe reverse transcriptase with random hexamers 
(Applied Biosystems; Foster City, CA, USA). Quantitative real-time PCR (Taqman) analysis 
was performed with an AbiPrism 7700 Sequence Detector System (Applied Biosystems) as 
described by Määttä et al. (2005). PCR primers and fluorogenic probes (human IL-6, IL-1β, 
IL-18, IL-12 p40, IFNγ, TNF-α, CCL3, CCL5, CXCL9, CXCL10, and CD86) were obtained 
as pre-developed reagents from Applied Biosystems. Endogenous 18S rRNA was used for 
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standardization of the signals. The results were expressed as fold differences when compared 
to the unexposed controls at each time point. 
4.5.2 ELISA (IV) 
The cell culture supernatants of DC were analyzed for IFNγ (Amersham Pharmacia), IL-23 
(Bender MedSystems GmbH; Vienna, Austria), IL-18 (MBL; Nagoya, Japan), TNF-α and IL-
12 p70 (eBioscience; San Diego, CA, USA) protein levels using commercial ELISA kits. The 
protocols obtained by the manufacturers were followed and the data were detected using an 
automated ELISA reader (Multiskan MS; Labsystems, Vantaa, Finland). The concentrations 
of IFNγ, TNF- α, IL-12 p70, IL-23 and IL-18 for each sample were obtained from the 
relevant standard curves. 
4.6 Statistical analysis 
The data were analysed with one-way analysis of variance (ANOVA) followed by Dunnet's 
multiple range test (II, III) or by Bonferroni's multiple comparison test (I, IV). The 
differences were considered as statistically significant at p<0.05. 
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5 Results 
The main effects of FB1 on neural and glial cell lines observed in this study are summarized in 
Table 5. 
 
Table 5. Summary of the main effects of FB1 on oxidative stress and apoptosis of neural and 
glial cells. 
Measurement Study
 U-118MG SH-SY5Y GT1-7 C6
Reactive oxygen 
species (ROS)
↑ 48, 72,         
144 h
ns ↑ 72, 144 h ↑ 144 h I, II
Glutathione (GSH) ↓ 48, 72,         
144 h
↓ 144 h ↓ 72, 144 h ↓ 48, 72 h I, II
Lipid peroxidation ↑ 24, 48,         
72 h
↑ 24, 72 h ↑ 144 h ↑ 72, 144 h I, II
Viability ↓ 72, 144 h ↓ 48, 72,       
144 h
↓ 48, 72,       
144 h
ns I, II
Caspase-3-like 
protease activity
↑ 12, 48, 72 h ns ↑ 48, 72,       
144 h
↑ 72 h II, III
Internucleosomal 
DNA fragmentation
↑ 144 h ↑ 48, 72,       
144 h
↑ 144 h ↑ 24, 48, 72, 
144 h
II, III
p53 protein ns ns ns ns II, III
Bcl-2 family proteins ns ns ns ns II, III
↑ increase; ↓ decrease; ns, no significant effects
Cell line and effect / exposure time
 
5.1 Oxidative stress induced by FB1 (I, II) 
Exposure to high doses of FB1 for long times evoked signs of oxidative stress in all cell lines 
studied. In U-118MG cells, ROS production increased after exposure to 100 µM FB1 for 48-
144 h or 10 µM FB1 for 72-144 h (II: Fig. 2). FB1 did not increase ROS production in SH-
SY5Y cells, but in GT1-7 and C6 cells, exposure to 100 µM FB1 for 72-144 h or 144 h, 
respectively, did result in increased ROS production (I: Fig. 2). 
The optimized HPLC-method used for the detection of malondialdehyde-thiobarbituric 
acid (MDA-TBA) complexes, indicating lipid peroxidation, proved to be stable and the results 
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were repeatable (I: Fig. 1; II: Fig. 1). In all cell lines, FB1 increased the lipid peroxidation, 
which was measured as an increase in the concentration of MDA. In U-118MG and SH-
SY5Y cells, the MDA concentration increased significantly already at 24 h, in GT1-7 cells at 
144 h, and in C6 cells at 72 h (I: Fig. 3; II: Fig. 3). 
Incubating cells with FB1 clearly decreased intracellular GSH levels in all cell lines. 
Exposure to 100 µM FB1 for 48-144 h, or 1 µM and 10 µM FB1 for 144 h, significantly 
decreased the GSH levels of U-118MG cells (II: Fig. 4). In SH-SY5Y cells, the GSH levels 
decreased only after exposure to 100 µM FB1 for 144 h. In GT1-7 cells, the GSH levels 
decreased significantly at 72 h with 100 µM FB1, and at 144 h with 1, 10, and 100 µM FB1. 
The GSH levels of C6 cells, on the other hand, decreased after exposure to 10 and 100 µM 
FB1 for 48 and 72 h (I: Fig. 4). 
5.2 Effects of FB1 on cell viability (I, II) 
FB1-exposure for 48 h or longer decreased the viability of U-118MG, SH-SY5Y and GT1-7 
cells as compared with untreated control cells. The viability of C6 cells was not statistically 
significantly affected by FB1. A significant decrease in the viability of U-118MG cells was 
noted after exposure to 100 µM FB1 for 72 h or 1, 10 or 100 µM FB1 for 144 h (II: Table 1). 
In SH-SY5Y and GT1-7 cells, 100 µM FB1 evoked cell death at 48-144 h of exposure (I: 
Table 1).  
5.3 Apoptosis in neural and glial cells exposed to FB1 
(II, III) 
Exposure to FB1 resulted in p53 independent apoptosis in all cell lines studied. The highest 
dose of FB1 (100 µM) caused a significant increase in caspase-3-like protease activity in U-
118MG cells at 12, 48 and 72 h of exposure (II: Fig. 5). In SH-SY5Y cells, no significant 
changes in caspase-3-like protease activity were observed. However, at 24 h, 100 µM FB1 
increased the caspase-3-like protease activity, although the increase was not statistically 
significant. The caspase-3-like protease activity in GT1-7 cells did increase after exposure to 
100 µM FB1 for 48-144 h, and exposure to 100 µM FB1 for 72 h also increased the activity in 
C6 cells (III: Fig. 1-3). 
As a consequence of FB1-exposure, internucleosomal DNA fragmentation occurred in all 
cell lines. Formation of DNA-ladders on agarose gels were seen in U-118MG cells at 144 h 
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with 10, 30 and 100 µM FB1 (II: Fig. 6), in SH-SY5Y cells at 48-144 h with 30 and 100 µM 
FB1, in GT1-7 cells at 144 h with 100 µM FB1, and in C6 cells at 24-144 h with 10 and 100 
µM (III: Fig. 4). 
Immunoblotting of p53, pro-apototic Bax, or anti-apoptotic Bcl-2 family proteins (Bcl-2, 
Bcl-XL, Mcl-1) showed that exposure to FB1 had no effects on the expression of these 
proteins in any of the four cell lines, at any time points or concentrations, as compared to 
control cells (III: Fig. 5). 
5.4 Effects of FB1 on cytokine and chemokine 
expression (IV) 
The main effects of FB1 on the expression of cytokines and chemokines of DC are 
summarized in Table 6. 
 
Table 6. Summary of the main effects of FB1 on cytokine and chemokine levels of human 
DC. 
 
 LPS FB1 FB1 + LPS FB1 + LPS
Measurement
Effect as compared 
with LPS
IFNγ mRNA ns ↑ 6, 24 h ↑ 6 h ns
IFNγ protein ns ↑ 24 h ns ns
CXCL9 mRNA ↑ 6 h ↑ 6, 24 h ↑ 6 h ns
IL-6 mRNA ↑ 6, 24 h ns ns ↓ 6, 24 h
IL-1β mRNA ↑ 6, 24 h ns ↑ 24 h ↓ 6 h
CCL3 mRNA ↑ 6, 24 h ns ns ↓ 6 h
CCL5 mRNA ↑ 6, 24 h ns ↑ 24 h ↓ 6, 24 h
TNFα mRNA ns ns ns ns
TNFα protein ↑ 6, 24 h ns ↑ 6, 24 h ns
↑ increase; ↓ decrease; ns, no significant effects  
Exposure
Effect as compared               
with control
 
Exposure of human DC to 100 µM FB1 for 6 h or 24 h resulted in a significantly induced 
expression of IFNγ mRNA. At 6 h, but not at 24 h, the combined exposure to 100 µM FB1 
and 10 ng/ml LPS also induced the IFNγ mRNA expression. At the protein level, exposure 
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to FB1 for 24 h caused a significantly elevated expression of IFNγ. At 6 h, the IFNγ protein 
levels of none of the groups differed from those of the control cells. Moreover, FB1, alone (at 
6 h and 24 h) or together with LPS (at 6 h), induced the mRNA expression of the IFNγ-
regulated chemokine CXCL9. (IV: Fig. 1).  
During exposure to both LPS and FB1, FB1 inhibited the LPS-induced mRNA expression 
of the pro-inflammatory cytokines IL-6 and IL-1β, as compared to the situation in cells 
exposed only to LPS. Exposure to FB1 alone did not affect the expression of these cytokines. 
CCL3 and CCL5 are chemokines regulating the expression of pro-inflammatory cytokines. At 
6 h LPS induced the expression of CCL3 and CCL5 mRNA in DC, but co-exposure with FB1 
blocked the induction (IV: Fig. 2).  
The mRNA levels of TNFα in DC exposed to LPS, FB1 or FB1+LPS were not increased 
at any time point. At the protein level, exposure to LPS and FB1+LPS caused a marked 
increase in the expression of TNFα, but FB1 alone had no effects on the expression (IV: 
Table 1). 
No differences between control cells and LPS-, FB1- or FB1+LPS-treated cells were 
observed when studying the mRNA expression of IL-18 in DC. When studying the protein 
levels of IL-18 and IL-23 in DC, also no differences could be observed. IL-12 p40 and 
CXCL10 mRNA expression increased after exposure to LPS for 6 h and 24 h, whereas the 
mRNA levels were not affected by FB1. LPS induced IL-12 p70 at the protein level, but FB1 
did not affect the expression of this cytokine. 
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6 Discussion 
6.1 The ability of FB1 to induce oxidative stress and 
cytotoxicity in neural and glial cells 
In the first two studies (I, II), the effects of FB1 on ROS production were found to be cell 
line specific. The most marked effects were seen in U-118MG glioblastoma cells, in which 
ROS production increased already at 48 h. In GT1-7 and C6 cells, the effects were seen at 
later time points, whereas in SH-SY5Y cells, production of ROS was not significantly altered 
by FB1-exposure. The reason for the differences observed between the cell lines may be due 
to their different abilities to bind FB1 or alternatively to differences in sphingolipid 
metabolism, including variations in the expression of the enzymes participating in different 
stages of sphingolipid synthesis and turnover (Merrill et al., 1997, 2001; Soriano et al., 2005). 
There are only a few studies which have investigated ROS production in relation to FB1-
exposure, and none of them have detected elevated ROS levels. No effects on ROS 
production were seen in human fibroblasts exposed to 10-100 µM FB1 for up to 72 h, or in 
primary cultures of rat astrocytes after exposure to the same concentrations of FB1 for up to 
6 days (Galvano et al., 2002a, b). In the peritoneal macrophages of rats fed with FB1, as well 
as in adherent peritoneal cells, even decreased production of H2O2 was detected. This was 
thought to possibly suppress some of the macrophage immunologic mechanisms of the cells 
(Theumer et al., 2002). 
Lipid peroxidation has been recognized as a major consequence of FB1-exposure in 
various cells and organs, including rat liver, monkey kidney cells, rat glioblastoma cells and 
mouse embryonic fibroblasts (Abado-Becognee et al., 1998; Abel and Gelderblom; Mobio et 
al., 2000a, 2003). Our present studies (I, II) also detected increases in the lipid peroxidation of 
U-118MG, SH-SY5Y, GT1-7 and C6 cells after 48-144 h of exposure. As with the production 
of ROS, significant effects were only observed after exposure to doses of 10 and 100 µM of 
FB1. Contrary to our results, Mobio et al. (2003) observed clearly induced levels of lipid 
peroxidation in C6 cells with 9-36 µM of FB1 at 24 h. In our study, special attention was paid 
to the validation of the HPLC-conditions to develop an accurate method for the quantitative 
measurement of lipid peroxidation. The differences between our results and those obtained 
by Mobio et al. (2003) may thus most probably be due to differences in the analytical 
conditions, or possibly to differences in experimental designs or cell culture conditions. 
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FB1 clearly decreased the GSH levels in all of the cell lines studied (I, II). These results are 
consistent with the observations on ROS production and lipid peroxidation. The fact that 
GSH levels decreased only after 48-144 h indicates that this was a response to oxidative stress 
occurring in the cells after exposure to FB1, rather than a response to reactive metabolites 
formed directly from FB1. The effects of FB1 on GSH have not been studied in neural cells 
before, but decreased GSH levels have been observed in murine liver cells, and in rat liver 
and spleen (Bondy et al., 1997; Atroshi et al., 1999). On the contrary, GSH levels increased in 
the kidneys of mice and in rat liver after FB1-treatments (Bondy et al., 1995, 1997). 
100 µM of FB1 was cytotoxic to U-118MG cells after incubation times of 72 or 144 h, and 
at concentrations of 1 and 10 µM also at 144 h (Study II). In SH-SY5Y and GT1-7 cells, 
decreases in cell viability were observed after exposure to 100 µM FB1 for 48, 72 and 144 h 
(Study I). In C6 glioma cells, we did not observe any statistically significant signs of 
cytotoxicity although Mobio et al. (2000a) reported that exposure to 9 µM FB1 for 24 h 
seemed to decrease the viability of these cells. We measured cell viability by the addition of 
propidium iodide, a compound that mainly detects necrotic cells. In necrosis, the integrity of 
the plasma membrane is lost, and propidium iodide can enter the cell and react with nucleic 
acids. Early apoptotic cells show intact membranes and are impermeable to propidium iodide, 
but late apoptotic cells, which have lost the integrity of their plasma membrane, may permit 
access to propidium iodide (Smolewski et al., 2002). Mobio et al. (2000a), on the other hand, 
studied cell viability by the trypan blue exclusion test. The difference between their study and 
our results may thus be attributable to the method used for the assessment of cell death, or to 
the cell culture conditions. 
The results of the present studies, showing that FB1 causes oxidative stress and is 
cytotoxic to neural cells only at high concentrations, are supported by other in vitro studies 
(Yoo et al., 1996; Bouchet et al., 2004). However, already very low concentrations of FB1 can 
cause systemic toxicity, which is probably due to the general inhibition of ceramide synthase 
(Wang et al., 1991). Therefore, it is problematic, and most likely not relevant, to make direct 
comparisons of FB1-doses being cytotoxic in vitro with doses causing general toxicity in vivo.  
The brain has a high lipid content, the levels of free radical scavenging enzymes are low, 
and the rate of oxidative metabolism is high (Halliwell and Gutteridge, 1985; LeBel and 
Bondy, 1991; Halliwell, 1992). Therefore the brain has been considered as being especially 
susceptible to ROS attack, and the results showing FB1-induced oxidative stress in neural and 
glial cell lines should not be dismissed lightly. 
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6.2 Mechanisms responsible for apoptosis induced by 
FB1 in neural and glial cells 
Activation of caspases followed by apoptosis are believed to be consequences of oxidative 
stress, i.e. ROS production, lipid peroxidation and reduced levels of GSH (Slater et al., 1995; 
van den Dobbelsteen et al., 1996; Ghibelli et al., 1998; Higuchi, 2003). Therefore, we studied 
whether FB1, in addition to its ability to cause oxidative stress, could also induce apoptosis in 
neural and glial cell lines. The results indicated that apoptosis occurs in all of the cell lines 
studied, but with clear differences in the time- and dose-response profiles (II, III).  
In U-118MG and GT1-7 cells, activation of caspase-3-like protease occurred at early time 
points (12 h and 48 h respectively), and was followed at later time points by increased ROS 
production, lipid peroxidation, decreased GSH levels and DNA fragmentation. This sequence 
of events indicates that in these cell lines, activation of caspases is not a consequence of 
oxidative stress. In fact, caspase-3 activation could be one of the triggers, activating oxidative 
stress-related factors prior to DNA fragmentation and cell death. It would be interesting to 
study the effects of addition of a caspase-3 inhibitor, to see whether oxidative stress would 
still occur after FB1-exposure. 
In C6 cells, caspase-3 activation was seen only at 72 h, although DNA fragmentation 
occurred already at 24 h. However, a slight increase in caspase-3 activity was seen after 
exposure to 100 µM FB1 for 24 h, and may partly explain the DNA fragmentation observed 
at that early time point. Decreased cell viability and DNA fragmentation occurred in SH-
SY5Y cells already at 48 h, but no statistically significant increase in ROS production or 
activation of caspase-3 could be observed at any of the time points. In addition, lipid 
peroxidation and decreased GSH levels were observed only after exposure to the highest FB1-
dose for 144 h. Activation of caspase-3 is usually involved in apoptosis, irrespective of which 
pathway (death receptor or mitochondrial, see Fig. 7) is initiated. However, recently some 
reports have focused on a type of caspase-independent cell death (Lockshin and Zakeri, 2002, 
2004; Bröker et al., 2005). It has been claimed that, in addition to the normal programmed 
cell death resulting in apoptosis, there are also other forms of programmed cell death. One 
proposed model is the apoptosis-like death, which includes chromatin condensation, this 
being perhaps less complete than in "traditional" apoptosis (Leist and Jäättelä, 2001). The 
mechanisms behind caspase-independent cell death still need to be clarified, but it is tempting 
to speculate that the DNA fragmentation observed in SH-SY5Y cells may be related to this 
kind of model for programmed cell death. 
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Figure 7. A schematic view of the pathways possibly involved in FB1-induced activation of 
caspase-3 followed by apoptosis. Mechanisms which according to our studies (II, III) are not 
involved in apoptosis induced in glial and neural cell lines are marked with an X. As the figure 
shows, the events leading to apoptosis in the studied cell lines are most probably activated via 
CD95 or TNF-receptors. The mitochondrial pathway may be involved in apoptosis induced 
by FB1 via the activation of Bid, causing cytochrome c release. For a more detailed picture of 
mechanisms involved in apoptosis, see Fig. 6. 
 
When studying the effect of exposure to FB1 on the expression of both pro- (Bax) and 
anti-apoptotic (Bcl-2, Bcl-X, Mcl-1) proteins of the Bcl-2 family, no changes in any of the 
four cell lines were observed. Furthermore, cells exposed to FB1 did not exhibit any 
differences in the levels of p53, a tumour suppressor which is known to activate Bax 
(Miyashita and Reed, 1995; Bratton and Cohen, 2001), as compared to controls. Therefore, 
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according to our results, apoptosis induced by FB1 does not involve changes in the expression 
of these proteins in neural and glial cell lines (Fig. 7). The basal expression levels of Bcl-2 
family proteins vary between different cell lines. C6 glioblastoma cells strongly express Bcl-XL 
and only weakly express Bcl-2 and Bax (Tjalkens et al., 2000). GT1-7 cells are also known to 
exhibit a low expression of Bcl-2 (Kane et al., 1993; Ellerby et al., 1996). SH-SY5Y cells, on 
the other hand, express lower levels of Bcl-XL and higher levels of Bcl-2 and Bax (Reed et al., 
1991; Tjalkens et al., 2000). The fact that the basal expression levels of the Bcl-2 family 
proteins do not have any impact on the FB1-induced effects on the expression of p53 or pro- 
or anti-apoptotic proteins strengthens the hypothesis that the p53 dependent mitochondrial 
Bcl-2 pathway is not important for FB1-induced apoptosis. 
In studies on the effects of FB1 on neonatal kidney cells and fibroblasts of different 
origin, it was shown that p53 was not required for FB1-induced apoptosis, because p53 
deficient primary mouse embryo fibroblasts underwent apoptosis in the same way as other 
types of fibroblasts. Moreover, Bcl-2 was not an effective inhibitor of apoptosis caused by 
FB1 (5-25 µM, 6-48 h) (Ciacci-Zanella and Jones, 1999; Jones et al., 2001). These findings 
support our results indicating that FB1-induced apoptosis is p53 and Bcl-2 family independent 
(Fig. 7). Moreover, the same studies also showed that a baculovirus gene, inhibitor of 
apoptosis (CpIAP), protected cells from apoptosis following FB1-treatment (Ciacci-Zanella 
and Jones, 1999; Jones et al., 2001). This gene is known to block apoptosis induced via the 
TNF pathway. In addition, it was shown that caspase-8 was cleaved, and the TNF receptor-
associated protein (TRAP)-2 was induced, which further indicates that FB1 activates apoptosis 
via binding to TNF-receptors (Ciacci-Zanella and Jones, 1999; Jones et al., 2001; Zhang et al., 
2001). In line with these results is the finding that FB1 can increase the expression of TNFα 
and caspase-8 in mouse liver and murine primary hepatocytes (Bhandari and Sharma, 2002b; 
Sharma et al., 2005). Contrary to the previously described findings, Mobio et al. (2003) did 
not observe any apoptotic effects of FB1 (3-36 µM, 24 h) in p53-null mouse embryonic 
fibroblasts. Furthermore, in mouse liver, an increase in the expression of Bax and Bcl-2 were 
observed after treatment with FB1 (Bhandari and Sharma, 2002a). Thus, in different cells or 
organs, different signalling pathways may be involved in the events leading to apoptosis. 
FB1 has to be considered as a potent inducer of apoptosis in neural and glial cells. 
According to the results of the present studies (II, III) and some others (Ciacci-Zanella and 
Jones, 1999; Jones et al., 2001; Zhang et al., 2001) it can be concluded that most likely FB1 
induces apoptosis via the receptor pathway and not via the mitochondrial pathway (Fig. 7). 
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This theory could possibly be confirmed in studies on activation of TNF- or CD95 receptors 
and caspase-8. Also studies on the cleavage of p22 Bid to p15 Bid, as well as on cytochrome c 
release could further illuminate the routes of FB1-induced apoptosis in neural and glial cells. 
6.3 Comparing the effects of FB1 on different neural 
and glial cell lines 
The studies which examined the ability of FB1 to induce oxidative stress and apoptosis in 
neural and glial cell lines of human, mouse and rat origin indicate that there are clear 
differences in the responses between different cell lines. Generally, no acute effects could be 
observed, but after exposure to high doses for prolonged times (usually at least 48 h, often up 
to 144 h), then all of the cell lines studied were affected (Fig. 8). 
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Figure 8. Summary of the effects of exposure of different cell lines to 10 µM and 100 µM 
FB1 for 144 hours. 
 
When taking into account the effects of FB1 on ROS production, lipid peroxidation, GSH 
levels, cell viability, caspase-3-like protease activity and DNA fragmentation (I, II, III), as well 
as the doses and time points when the effects were observed, the sensitivities of the cell lines 
may be classified as follows: human U-118MG glioblastoma cells > mouse GT1-7 
hypothalamic cells > rat C6 glioblastoma cells > human SH-SY5Y glioblastoma cells. 
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In a recent report it was shown that the immunocompetent cells of murine brain 
(microglial cells and primary astrocytes) may be the primary targets in the neurotoxicity 
induced by FB1. Neural cells, on the other hand, do not seem to be vulnerable to FB1-
dependent cytotoxicity (Osuchowski and Sharma, 2005). Similar results were also 
demonstrated with cultures of rat astrocytes and neurons (Monnet-Tschudi et al., 1999). In 
our studies, cell lines originating from humans, mice and rats were used, and therefore it is 
difficult to directly compare the results from different types of cell lines with each other. 
However, the results obtained in cells of human origin (U-118MG and SH-SY5Y) may be 
compared, and they reveal that U-118MG cells are much more sensitive towards FB1 than 
SH-SY5Y cells, confirming the previous observations (Monnet-Tschudi et al., 1999; 
Osuchowski and Sharma, 2005) that glial cells seem to be more sensitive towards the toxicity 
induced by FB1 than the neural cells. 
Glial cells are extremely important for the protection of neural cells. The deleterious 
effects of FB1 on glial cells may therefore also have harmful consequences on neural cells. As 
FB1 increases the ROS production in glial cells and causes cell death, these reactive 
metabolites may be released and thus also affect neighbouring cells, i.e. neurons. When 
significant amounts of glial cells die, the protection of neurons via the regulation of the 
surrounding chemical environment, formation of the myelin sheath, transport of nutrients 
and phagocytosis of invading micro-organisms is disturbed, which can have dramatic effects 
on the general function of the nervous system.  
6.4 Alterations in cytokine and chemokine profiles of 
dendritic cells 
DC represent the most important type of antigen presenting cells, which both initiate and 
modulate immune responses. DC progenitors in the bone marrow give rise to immature cells 
with a high phagocytic capacity, which are located in different tissues. During infection with 
pathogens or xenobiotic compounds, immature DC capture the antigens and migrate to 
lymphoid organs, mature and activate lymphocytes (Fig. 9) (Banchereau and Steinman, 1998; 
Banchereau et al., 2000). DC are known to express a number of chemokine receptors, and the 
cytokines and chemokines secreted are extremely important for the further mechanisms 
involved in the immunological defence against pathogens (Sallusto et al., 1998; Sozzani, 
2005). 
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Figure 9. The life cycle of dendritic cells. DC precursors enter tissues as immature DC. 
Antigen capture leads to migration to lymphoid organs where DC mature and cause 
lymphocyte activation. The activated lymphocytes then activate macrophages, eosinophils and 
natural killer cells. (Modified from Banchereau et al., 2000). 
 
We explored the effects of FB1, alone or together with LPS, on the expression of cytokine 
and chemokine proteins and mRNA in human PBMC-derived DC (study IV). To our 
knowledge results on the effects of FB1 on DC have not been published before. LPS is a 
major recognition marker and activator of the innate immune system against Gram-negative 
bacteria, which are common human pathogens. The environmental prevalences of both FB1 
and LPS are high, which indicates that co-exposure to both compounds is most probably 
rather frequent (Dutton, 1996; Heederik et al., 2000; Liebers et al., 2006). It has also been 
indicated that LPS may augment the toxic effects of different kinds of xenobiotics (Ganey 
and Roth, 2001). Therefore it is possible that exposure to FB1 may interfere with the 
development of efficient protective inflammatory reactions against invading LPS-containing 
pathogens. 
Exposure of DC to 100 µM of FB1 for 6 or 24 h increased the expression of the cytokine 
IFNγ, as compared to the situation in control cells. In addition, FB1 increased the levels of 
CXCL9, which is a chemokine known to be induced by IFNγ (Salazar-Mather et al., 2000). 
Thus, the induction of CXCL9 confirms our observations on the increased levels of IFNγ. 
IFNγ is known to regulate almost 500 genes, and participates in the recruitment of 
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monocytes, T-cells, eosinophils and basophils, Th1 phenotype development, immunoglobulin 
E (IgE) downregulation and IgG upregulation (Fig. 10) (Boehm et al., 1997).  
 
 
 
 
 
 
 
 
Figure 10. Summary of some of the main mechanisms involved in the expression of the 
cytokine IFNγ. ↑ increase; ↓ decrease. (See Boehm et al., 1997; Salazar-Mather et al., 2000; 
Teixera et al., 2005). 
 
In previous studies, increased IFNγ levels have been observed after FB1-exposure in livers 
of mice (Bhandari and Sharma, 2002a), in bronchoalveolar lavage fluid of pigs (Halloy et al., 
2005), and in vitro in pig PBMC (Taranu et al., 2005). Previously, it was thought that DC 
cannot express IFNγ, but recently evidence has accumulated that both human and mouse DC 
are capable of producing IFNγ. However, it cannot be ruled out that a part of the IFNγ 
detected in DC populations in vitro may originate from contaminating cells (Frucht et al., 
2001; Bogdan and Schleicher, 2006; Fricke et al., 2006). IL-12, IL-18 and IL-23 are the main 
cytokines responsible for the induction of IFNγ (Fig. 10) (Ohteki et al., 1999; Re and 
Strominger, 2001; Borish and Steinke, 2003; Teixera et al., 2005). We did not observe any 
FB1-induced increases in protein or mRNA levels of these cytokines, and thus the mechanism 
whereby IFNγ is up-regulated in DC remains unclear. Further studies will therefore be 
needed to clarify the factors participating in the elevation of IFNγ in these cells. One 
interesting issue would be to study whether FB1 can alter the expression of the rather recently 
discovered cytokine, IL-27, which is known to be expressed by DC and macrophages, and 
which is claimed to participate in the induction of IFNγ (Villarino et al., 2004; Hunter, 2005; 
Steinke and Borish, 2006). 
When studying the effects on the expression of the pro-inflammatory cytokines IL-6 and 
IL-1β in DC, it was clearly seen that FB1 could decrease the elevated expression levels 
induced by LPS. FB1 also inhibited the LPS-induced expression of the chemokines CCL3 and 
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CCL5, which are known to induce pro-inflammatory cytokines (Appay and Rowland-Jones, 
2001; Maurer and von Steubt, 2004). Therefore, it seems likely that the inhibitory effects of 
FB1 on the elevated levels of CCL3 and CCL5 result in a decrease of IL-6 and IL-1β. An 
inhibition of the LPS-induced decline in IL-1β levels has also been observed in mouse liver 
and brain (Osuchowski et al., 2005). However, in contrast to our results, FB1 was reported to 
potentiate the LPS-induced expression of IL-6 (Osuchowski et al., 2005). When studying the 
effects of exposure to FB1 alone in primary swine alveolar macrophages, a significant decrease 
in mRNA levels of IL-1β was observed (Liu et al., 2002). 
The general inhibition of ceramide synthase induced by FB1 results in elevated levels of 
sphinganine, and to a lesser extent sphingosine, and their metabolites sphinganine-1-
phosphate and sphingosine-1-phosphate (S1P) (see Fig. 4). Recently it has been shown that 
S1P may participate in mediating the migration of DC (Idzko et al., 2002; Czeloth et al., 2005; 
von Wenckstern et al., 2006). It has also been shown that S1P, together with LPS, can inhibit 
the secretion of IL-12 and TNFα by DC (Idzko et al., 2002). Thus it may be possible that the 
inhibition of ceramide synthase by FB1 and the subsequent increase in S1P may be the 
mechanism responsible for at least some of the effects on DC observed in our study. 
It is evident that FB1 is able to induce immunotoxicity by affecting the cytokine and 
chemokine profiles of human DC. As this cell type is affected, it cannot be ruled out that also 
other important cells of the immune system, for example macrophages, may be affected. The 
entire immunological defence system is built up of chain reactions. If one link in the chain is 
either activated or inhibited, this may have widespread effects on the whole system. The fact 
that FB1 is able to affect the immune system may also be relevant for the nervous system, i.e. 
it may possibly have some effects on the phagocytic capacity and other activities of glial cells, 
and thereby on the functions of the nervous system in general. 
6.5 Importance of the results 
This study focuses on FB1, which is only one out of 400 known mycotoxins. However, it can 
be considered as one of the most important mycotoxins because of its abundance and its 
well-known toxicity. The chemical structure of the fumonisins is unique for this group of 
mycotoxins, and most of the toxic effects are attributable to its structure. FB1 differs from the 
other most frequently occurring mycotoxins (e.g. aflatoxins and ochratoxin A), which usually 
cause mainly liver and kidney toxicity, since it also affects the lungs and the nervous tissue.  
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The results of this study provide new information about the neuro- and immunotoxicity 
induced by FB1. In particular, the observation that human glial cells seem to be more sensitive 
towards oxidative stress and apoptosis than neural cells is important with respect to the in vivo 
exposure situation. Also the observation that dendritic cells are affected by FB1 is important, 
as this may result in a broad spectrum of events involving other cell types. 
In vitro studies using different types of cells are very important because they can provide 
detailed information about mechanisms behind the toxic effects. When combining the results 
of different specific cells, it may be possible to obtain a clearer picture of the most important 
mechanisms behind the toxicity of a certain compound. If one wishes to understand the 
effects in vivo, it is also useful to know which types of cell-cell interactions may be present. It 
should also be remembered that making direct comparisons of dose-effects in vitro with in vivo 
situations is most probably not relevant. The results of our in vitro studies, showing significant 
effects only with high concentrations of FB1, indicate however that low doses of this 
mycotoxin probably do not cause acute neuro- or immunotoxicity in vivo. 
FB1 has mainly been detected in food items. However, mycotoxins are commonly present 
in the environment, for example in domestic residences and in working places, and therefore 
it would be important to device convenient methods for routine detection of different kinds 
of mycotoxins. It is also important to remember that co-occurrence of different moulds and 
mycotoxins is common, and the possibility of a synergistic effect should not be ignored 
(Tajima et al., 2002; Speijers and Speijers, 2004; McKean et al., 2006). In any risk assessment 
of FB1 it is very important to take into account exposure levels, exposure routes (via food, 
indoor air, and contaminated building materials) as well as all types of possible health effects. 
Thus, the results of the present study can shed new light on important aspects of this 
mycotoxin. 
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7 Summary and conclusions 
The toxic effects of the mycotoxin FB1, which is produced by Fusarium verticillioides, have been 
studied in a number of different animals, organs and cell types. The main mechanism behind 
the toxic effects of FB1 is the inhibition of the enzyme ceramide synthase, which results in 
disruption of normal sphingolipid metabolism. The aim of this study was to clarify whether 
FB1 can cause oxidative stress, necrosis or apoptosis in different types of neural and glial cell 
lines, as well as on investigating whether FB1 affects the cytokine and chemokine profiles of 
dendritic cells.  
The results of this study show that FB1 can cause oxidative stress in human U-11MG, 
human SH-SY5Y, mouse GT1-7 and rat C6 cells. The signs indicative of oxidative stress 
observed in these cell lines include increased production of reactive oxygen species, lipid 
peroxidation and decreased levels of intracellular glutathione. The sensitivities of the cell lines 
towards FB1 vary, depending on which parameter is studied. However, responses were 
commonly seen only after exposure to doses of 10 or 100 µM of FB1 for at least 24 h, in 
many cases up to 144 h. 
Exposure to FB1 resulted in a decreased viability of U-118MG, SH-SY5Y and GT1-7 
cells. In contrast, the viability of C6 cells was not affected even after exposure for 144 h. The 
differences between the sensitivities of the cell lines may be due to their different abilities to 
bind FB1 or to differences in the expression of enzymes participating in sphingolipid 
metabolism. 
When studying mechanisms related to apoptosis, it was observed that FB1 is able to 
induce apoptosis in U-118MG, SH-SY5Y, GT1-7 and C6 cells. Internucleosomal DNA 
fragmentation occurred in all four cell lines and activation of caspase-3-like protease was seen 
in all cell lines, except SH-SY5Y. No changes in the expression of p53, Bax, Bcl-2, Bcl-X or 
Mcl-1 proteins were observed, indicating that the p53-dependent mitochondrial Bcl-2 
pathway is not important for the FB1-induced apoptosis in these types of cells. 
In summary, the studies on oxidative stress, viability and apoptosis indicate that, when 
comparing cell lines of human origin, glial cells are more sensitive towards the toxicity 
induced by FB1 than cells of neural origin. 
In human dendritic cells, FB1 affected the expression of some cytokines and chemokines. 
FB1 caused a clear induction of IFNγ mRNA and also of the mRNA of the chemokine 
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CXCL9, which is known to be induced by IFNγ. LPS induced the levels of the pro-
inflammatory cytokines IL-6 and IL-1β, as well as the chemokines CCL3 and CCL5, but co-
exposure of the cells to FB1 and LPS did not result in any elevation of the expression of these 
cytokines and chemokines. The results indicate that FB1 has the capacity to modulate the 
immune responses of DC. Therefore, it is very likely that it also affects other types of cells 
participating in the immune defence system, which may have widespread effects on the 
immunological reactions in general. 
 
When evaluating the toxicity potential of FB1, it is important to consider the effects on 
different cell types and cell-cell interactions. The present results shed new light on this puzzle, 
especially concerning the mechanisms behind FB1-induced oxidative stress, apoptosis and 
immunotoxicity, as well as the varying sensitivities of different cell types towards FB1. 
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